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Summary 
 
The overall goal of this thesis was to evaluate if herpes simplex virus type-1 (HSV-1) 
amplicon vectors are possible candidate vectors to establish a new vaccine vector platform 
against rotavirus (RV) infections and Foot-and-mouth disease virus (FMDV). 
RV infections lead to severe gastroenteritis in young children, killing more than half a million 
infants worldwide per year. Almost all children both in developing and developed countries 
are infected with RV during their first years of life and even advanced levels of sanitation and 
hygiene appear unable to control the spread of RV infections, which highlights the urgent 
need for the development of an effective prophylactic anti-RV vaccine. 
FMDV is one of the most devastating viruses affecting cloven-hoofed animals, like cattle, 
sheep, goats and pigs. Foot-and mouth disease (FMD) represents one of the most important 
epidemics of farm animals and continues to be of major economic importance across the 
world. FMDV spreads rapidly in a susceptible population and presently, the disease is 
controlled by slaughter of infected or in-contact animals, and quarantine and 
decontamination for the whole region. An effective and safe vaccine against FMD would be 
most desirable. 
Virus-like particles (VLPs) are most promising candidates for the development of vaccines, 
as they are very similar to the equivalent virus, but safer than attenuated virus vaccines, 
since they do not contain genetic material. VLPs mimic the overall structure of virus particles 
and are therefore readily recognized by the immune system as they represent viral antigens 
in a more authentic conformation. 
In the present work, HSV-1 amplicon vectors have been developed that co-express the 
structural genes required for capsid assembly, of the two RNA viruses, FMDV and RV. The 
designed amplicon vectors provide a high safety level as they can be produced by using a 
helper virus-free packaging system leading to the absence of expression of any HSV-1 gene. 
The high transgene capacity (150 kbp) allows the insertion of several genes, and the 
simultaneous expression of the different structural genes of FMDV and RV was achieved by 
introducing internal ribosome entry site (IRES) sequences. Expression of the individual 
genes alone or in combination was demonstrated by Western and immune fluorescence 
analyses. The capability of the vectors to support the production of RV and FMDV VLPs in 
the vector-transduced cells was demonstrated by electron microscopy. 
Inoculation of mice with these vectors resulted in the expression of viral antigens, followed by 
induction of immune responses and a variable level of protection against challenge with a 
high dose of wild type virus. Moreover, the results obtained by vaccinating mice with 
inactivated vectors showed that induction of immune responses required de novo synthesis 
of proteins from the vectors and the contamination of vector stocks with preformed proteins is 
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not contributing to the immune responses, as demonstrated with inactivated amplicon 
vectors that do not support protein synthesis. In the case of FMDV amplicon vectors, 
induction of immune responses and protection against challenge were higher with amplicon 
vectors than with adenovirus vectors expressing the same FMDV proteins and required no 
adjuvants. 
Taken together, the results presented in this work suggest that HSV-1 amplicon vectors are 
attractive candidates for the development of complex but safe genetic vaccines against viral 
infections. 
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Zusammenfassung 
 
Rotaviren zählen bei Mensch und Tier weltweit zu den wichtigsten Erregern schwerer, 
dehydrierender Gastroenteritis. Weltweit führen Rotavirusinfektionen jährlich zu ca. 600'000 
Todesfällen bei Kleinkindern unter 5 Jahren, und 30-80% aller Hospitalisierungen sind auf 
Rotavirusinfektionen zurückzuführen. Vor allem in Entwicklungsländern und Dritte Welt 
Ländern beträgt die Letalität bis zu 98%, da das Gesundheitssystem schlecht ausgebaut ist. 
Rotaviren sind als ein individueller Genus (Gattung) in der Familie der Reoviridae 
klassifiziert. Ihr Durchmesser beträgt 70-75 nm, sie sind icosahedral, dreischichtig und 
unbehüllt. Das virale Genom wird durch das sogenannte Core, bestehend aus 120 Kopien 
von VP2, umschlossen. Die VP2 Schicht ist durch die mittlere Schicht umschlossen, die aus 
780 Kopien des Hauptproteins VP6 besteht. Die äußerste Schicht der Hülle wird aus zwei 
Proteinen gebildet, dem Glykoprotein VP7 und dem Spikeprotein VP4. Das Virion ist 
komplex und erscheint im Elektronenmikroskop als Rad-ähnliche Struktur, deshalb der Name 
Rotavirus (Latein rota = Rad). Das Genom besteht aus 11 Segmenten doppelsträngiger 
RNA, die zusammen für 6 Strukturproteine (VP1-VP7) und, abhängig vom Virusstamm, 5 
oder 6 Nichtstrukturproteine (NSP1-NSP6) kodieren. Das segmentierte Genom erlaubt die 
Bildung von Reassortanten (Genaustausch zwischen unterschiedlichen Rotaviren) und 
ermöglicht damit die Entstehung neuer Rotavirus Stämme und eine grosse Diversität dieser 
Viren. 
Maul und Klauen Seuche (MKS) ist eine akute, hochkontagiöse Viruserkrankung der 
Wiederkäuer und der Schweine. MKS ist weltweit eine der verheerendsten 
Viruserkrankungen landwirtschaftlicher Nutztiere, da die Seuche innerhalb kürzester Zeit alle 
Klauentiere eines Betriebes befallen kann und schwere wirtschaftliche Schäden verursacht. 
Das MKS Virus gehört zur Familie Picornaviridae (pico = klein), Gattung Aphtovirus und ist 
mit einem Durchmesser von 25-30 nm eines der kleinsten RNA Viren. Das Virion ist 
unbehüllt und hat eine icosahedrale Symmetrie. Die Proteinhülle (Kapsid) besteht aus einem 
dicht gepackten Arrangement von 60 Einheiten (Protomeren), wobei jedes aus 4 
Strukturproteinen besteht, VP1, VP2, VP3 und VP4, wobei VP4 an der Innenseite des 
Kapsids lokalisiert ist und mit dem RNA Genom assoziiert ist. Das Genom besteht aus 
einzelsträngiger RNA mit positiver Polarität, ist nicht segmentiert und enthält einen einzigen 
offenen Leserahmen (ORF), der für ein Vorläuferprotein (Polyprotein) kodiert, welches noch 
während seiner Synthese proteolytisch in die verschiedenen Viruskomponenten gespalten 
wird, die Struktur- und Nichtstrukturproteine, sowie die viralen Enzyme. Die P1 Region des 
Vorläuferproteins enthält die Strukturproteine VP1-4; die P2 und P3 Regionen die 
Nichtstruktur-proteine, welche eine Rolle bei der Replikation spielen. Die Spaltung des 
Polyproteins erfolgt durch Virus-eigene Proteasen. 
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Das Ziel dieser Arbeit war, mit Hilfe von sogennanten Herpes simplex Virus Typ 1 (HSV-1) 
Amplikon Vektoren die Strukturgene von Rotaviren und MKS Viren in Zellen zu bringen, wo 
die Proteine der jeweiligen Virushülle hergestellt werden, die sich dann zu sogenannten 
virus-ähnlichen Partikeln (VLPs, virus-like particles) zusammenfügen, also leere Virushüllen, 
die aussehen wie das Virus, aber kein Genom besitzen. Die Strukturgene wurden in 
Amplikonplasmide kloniert, welche durch die Ko-Transfektion von Zellen mit dem 
Amplikonplasmid und einem HSV-1 Helfergenom in infektiöse Amplikonpartikel verpackt 
wurden, welche dann zur Transduktion von Zellen benützt wurden. 
Im Fall des Rotavirus exprimieren die Amplikonvektoren die drei Strukturproteine VP2, VP6 
und VP7, welche zusammen das dreischichtige Rotaviruskapsid bilden. Für das MKS Virus 
wurde das Vorläuferprotein P1, welches die vier Strukturproteine der Virushülle VP1, VP2, 
VP3 und VP4 enthält zusammen mit der Virus-eigenen Protease 3C, welches das 
Vorläuferprotein spaltet, in die Vektoren kloniert. 
Mittels Immunfluoresezenz und Western Blot konnte die Synthese der Proteine in Vektor-
infizierten Zellen mittels jeweiligen Protein-spezifischen Antikörpern nachgewiesen werden, 
ebenso konnte mit Elektronenmikroskopie gezeigt werden, dass sich die Strukturproteine 
tatsächlich zu VLPs zusammenfügen.  
Um zu untersuchen, ob sich die Amplikon Vektoren als eine mögliche Alternative für die 
Entwicklung von neuen Impfstoffen eignen, wurden Mäuse mit den Vektoren geimpft und die 
spezifische Antikörperantwort untersucht. Es konnte gezeigt werden, dass die 
Amplikonvektoren eine Virus-spezifische Immunreaktion auslösen und dass diese Antwort 
auf der Neusynthese der Proteine vom Vektor beruht, da fast keine Antikörper gebildet 
wurden, wenn die Vektoren vorher inaktiviert wurden. 
Desweiteren wurde getestet, ob die Mäuse gegen eine Infektion geschützt sind, wozu ein 
sogenanntes Challenge Experiment durchgeführt wurde, wobei die vorher geimpften Mäuse 
mit Virus infiziert wurden. In beiden Fällen konnte gezeigt werden, dass die geimpften Mäuse 
teilweise gegen die jeweilige Infektion geschützt waren. 
Zusammenfassend kann aus den Resultaten dieser Arbeit geschlossen werden, dass die 
Amplikonvektoren ein gutes Instrument darstellen, um eine neue Art von Impfstoffen gegen 
MKS Virus und Rotavirus Infektionen herzustellen. 
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1 Introduction 
1.1 Rotavirus 
1.1.1 History 
The first rotaviruses (RVs) described, based on pathology and epidemiology, were murine 
strains classified under the general description as the agents responsible for “epizootic 
diarrhea of infant mice” (EDIM) (12, 87). In 1963, the first RVs were visualized by electron 
microscopy (1) and in the same year also observed in rectal swabs of monkeys (66). The 
agents were described as 70 nm particles that had a wheel-like appearance when they are 
observed by negative-stain electron microscopy (Figure 1), a characteristic that suggested 
the name of the virus, “rota” viruses from the Latin word for wheel (34). The presence of such 
particles also in stool of calves with diarrhea demonstrated the association of this virus with a 
diarrheal disease in cattle (77). The correlation of the described virus with severe diarrhea in 
young children was reported first in 1973 by Bishop et al (9), when virus particles were found 
by electron microscopy in duodenal biopsies from children with acute gastroenteritis. 
 
Figure 1: Rotavirus particle. Negative-stain electron microscopy of purified and inactivated Rotavirus strain 
SA11. (A. Laimbacher and E. Schraner, University of Zurich, Switzerland) 
Besides their distinctive morphologic features, RVs were shown to share a group antigen 
(50) and were therefore classified as members of the genus Rotavirus within the family of the 
Reoviridae (70). The finding of particles in pigs with the same morphology but lacking the 
common group antigen (11, 101) led to the establishment of six additional RV groups (B to 
G) with the original RV strain classified as group A. 
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In a relatively short period, investigators from many countries reported the detection of 
rotaviruses in faeces of paediatric patients with diarrhoeal illness, and it was soon 
established that rotaviruses were the long–sought-after major viral etiologic agents of severe 
diarrhoea of infants and young children in both developed and developing countries, 
consistently outranking in importance other known etiologic agents of severe diarrhoea. 
1.1.2 Virus Classification 
The rotaviruses compose a genus within the family Reoviridae and share common 
morphologic and biochemical properties: (a) mature virus particles are about 75-100 nm in 
diameter and posses a triple–layered icosahedral protein capsid composed of an outer layer, 
intermediate layer and an inner core layer; (b) 60 spikes extend from the smooth surface of 
the outer shell; (c) particles contain an RNA-dependent RNA polymerase and other proteins 
capable to produce capped RNA transcripts; (d) the virus genome contains 11 segments of 
double-stranded RNA (dsRNA); (e) RVs of the same group are capable of genetic 
reassortment; (f) virus replication occurs in the cytoplasm of infected cells; (g) virus 
cultivation in vitro is facilitated by treatment with proteolytic enzymes, which enhances 
infectivity by cleavage of an outer capsid spike polypeptide; and (h) the viruses exhibit a 
unique morphogenic pathway (i.e., virus particles are formed by budding into ER) and 
enveloped particles are evident transiently at this stage of morphogenesis. Mature particles 
are non-enveloped, and these virions are liberated from infected cells by cell lysis or by non-
classical vesicular transport in polarized epithelial cells (29, 31). 
The classification scheme of rotaviruses is based on genome composition and 
immunological reactivities of three of its components: (i) The middle layer capsid protein VP6 
designates the group, of which at least seven (A-G) are reported until now. Among group A 
RVs, two major subgroups (I and II) exist. (ii) A binary classification system based on the two 
surface proteins VP4 and VP7 has been established, by which G types (VP7-specific, G for 
glycoprotein) and P types (VP4-specific, P for protease-sensitive protein) are distinguished. 
So far, at least 16 G types and 27 P types have been detected, of which at least 11 G and 11 
P types infect humans. Group A RVs are the most common cause of RV diseases in 
humans. 
Various combinations of VP4 and VP7 types have been observed in RV isolates as VP4 and 
VP7 are encoded by different RNA segments, which leads to reassortments in double-
infected cells. 
1.1.3 Virion structure and proteins 
The mature infectious rotavirus particle is made of three concentric icosahedral protein 
layers. The complete virion is called a triple-layered particle containing a non-enveloped, 
icosahedral capsid with a diameter of approximately 75-100 nm (100 nm including the 
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spikes). These three protein layers encapsidate the viral genome of 11 segments of ds RNA 
(Figure 2). 
 
Outer capsid
VP4 VP7
Middle capsid
VP6 VP2
VP1, VP3
Inner capsidMiddle
capsid
Inner
 capsid
 
Figure 2: Virion structure of Rotavirus. The virion is composed of three protein layers mainly formed by four 
structural proteins: The inner capsid is formed by 120 copies of VP2 arranged as dimers; the middle capsid is 
made of 780 copies of VP6 forming trimers; the outermost layer is composed of 780 copies of VP7-trimers 
decorated with 60 spikes formed by 120 copies of VP4 (Adapted from ViralZone: www.expasy.org/viralzone, 
Swiss Institute of Bioinformatics).   
The 11 ds RNA segments of the rotavirus genome encode for six structural and six non-
structural proteins. Based on their molecular weights the structural proteins are named as 
viral protein (VP), with VP1 for the largest until VP8*, one of the two proteolytic fragments of 
VP4, as the smallest (Table 1). The capsid of the mature virion is formed by six structural 
proteins, whereas the six non-structural proteins (NSPs) are essential for virus replication 
cycle or interact with host proteins to influence pathogenesis or the immune response. They 
are found in infected cells but are not incorporated into the mature virion.  
 
Table 1: dsRNA segments and proteins of rotavirus strain SA11 
Genome 
Segment 
Gene 
Product(s) 
Protein 
Size 
kDa 
Location in 
Virus 
Particle 
Copies/ 
Particle 
Functions and 
Properties 
1 VP1 125 Inner capsid 12 
RNA-dependent RNA polymerase, 
part of minimal replication complex, 
part of virion transcription complex 
with VP3, ss-RNA binding 
2 VP2 102.4 Inner capsid 120 Inner capsid structural protein, 
non-specific ss & dsRNA-binding 
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activity, required for replicase 
activity of VP1 
3 VP3 98.1 Inner capsid 12 
Guanylyltransferase, 
methyltransferase, non-specific ss 
& dsRNA binding, part of virion 
transcription complex with VP1 
4 
VP4 86.8 
Outer capsid  
spike 120 
VP4 dimers form spikes, 
hemagglutinin, cell attachment, P-
type neutralizing antigen, cleavage 
by trypsin into VP5* and VP8* 
enhances infectivity 
VP5* 60 
VP8* 28 
5 NSP1 58.7 Nonstructural 0 
Associates with cytoskeleton, 
extensive sequence diversity 
between strains, role in 
suppressing host INFa response 
6 VP6 44.8 Middle 
capsid 780 
Major virion protein, homotrimeric 
structure forming middle layer, 
subgroup antigen, required for 
transcription 
7 NSP3 34.6 Nonstructural 0 
Homodimer, involved in 
translational regulation and host 
shut-off, RNA-binding 
8 NSP2 36.7 Nonstructural 0 
NTPase and helicase, RNA and 
NSP5 binding, involved in 
viroplasm formation 
9 VP7 37.4 Outer capsid 780 
Outer capsid structural 
glycoprotein, G-type neutralization 
antigen, rER transmembrane 
protein, Ca-binding 
10 NSP4 20.2 Nonstructural 0 
Viral enterotoxin, receptor for 
budding of double-layered particles 
through ER, rER transmembrane 
protein, modulates intracellular Ca 
levels and RNA replication, 
secreted cleavage product 
11 
NSP5 21.7 Nonstructural 0 
Interacts with NSP2 and NSP6, 
homomultimers, 
hyperphosphorylated, component 
of viroplasm, essential for viral 
replication, protein kinase 
NSP6 11 Nonstructural 0 
Product of 2nd out-of-frame ORF, 
interacts with NSP5, located in 
viroplasm 
References: (4, 31); Mertens and Bamford, 2003, http://www.reoviridae.org/dsRNA_virus_proteins/Rotavirus.htm  
 
One aim of this thesis was to produce virus-like particles (VLPs) containing VP2, VP6 and 
VP7. Therefore, these three structural proteins are described below in more detail. 
 
VP2. The innermost protein layer of the rotavirus virion is composed of 120 copies of VP2 
arranged as dimers. This layer surrounds the viral genome and RNA processing enzymes, 
including the RNA-dependent RNA polymerase VP1 and the capping enzyme VP3. The 
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particle structure at this level is referred to as the single-layer or core particle (93). 
Expression of VP2 in insect cells using recombinant baculoviruses resulted in assembly of 
VP2 proteins into core-like particles of 50 nm in diameter (56). The VP2 shell of rotavirus 
plays an important role in the structure and function of the core by interacting with trimers of 
VP6, which surround the VP2 layer and the shell is perforated with aqueous channels that 
transport nascent RNA out and metabolites in the core during transcription (127). The amino 
terminus of VP2 possesses a non-specific ss RNA and ds RNA-binding activity and is also 
essential for the incorporation of VP1 and VP3 into the core of the virion (57). Besides its 
scaffolding functions, VP2 also serves as cofactor for the activation of the viral polymerase 
VP1 to initiate the synthesis of viral ds RNA (72). 
 
VP6. VP6 is the major structural component of virions forming the intermediate layer, and it 
plays a key role in the overall organization of the virion structure because of its interactions 
with both outer capsid proteins, VP4 and VP7, and the core protein VP2. Particles carrying 
VP6 on the outside are called double-layered particles and are the transcriptionally 
competent form of the virus (93). This middle shell is made of 780 copies of VP6, which 
spontaneously form trimers. Trimerization and the formation of tubules is an intrinsic property 
of the VP6 protein, since it forms these structures in the absence of other viral proteins (30). 
These trimers can be dissociated and reassembled by changing pH (58). VP6 is important as 
a structural component to maintain the proper conformation or organization of the particle. 
The VP2-VP6 interaction defines the correct geometry of the virion (69) VP6 is both highly 
immunogenic and antigenic, and it is the protein targeted most often in diagnostic assays as 
it contains common epitopes shared by other group A viruses.  Co-expression of VP2 and 
VP6 from baculovirus vectors results in the formation of double-layered VLPs (20). 
 
VP7. VP7 is the second most abundant capsid protein and the major constituent of the outer 
layer. 780 copies of this glycoprotein, grouped as 260 trimers, together with 60 spikes of 
VP4, form the outer-most layer of the virion. VP7 is reported to be highly immunogenic and is 
inducing neutralizing antibodies. VP7 is localized to the endoplasmic reticulum (ER) of the 
cell, where it is retained as a membrane-bound protein before assembly into maturing virion 
particles (3). VP7 is co-translationally glycosylated as it is inserted into the membrane of the 
ER, and insertion is directed by a cleavage signal sequence found at the amino-terminus of 
the protein. The nucleotide sequence predicts an ORF of 326 amino acids (aa), which begins 
with an initiation codon with a weak consensus sequence. A second in-frame initiation codon 
precedes two regions of hydrophobic aa (H1 and H2), which can act as the signal sequence 
to direct VP7 to the ER, although the second is thought to be the major species used in cells. 
A third in-frame initiation codon is also present downstream from the second hydrophobic 
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domain in some strains (29). Studies to determine the signals leading to the retention of VP7 
to the ER have shown that VP7 does not contain the sequence KDEL found to confer 
retention for some other ER proteins. There are several studies reporting regions in the ORF 
responsible for retention of VP7 in the ER and also that these residues are critical for 
retention, but the method by which VP7 remains in the ER is unclear (65).  
1.1.4 Rotavirus Lifecycle 
RVs have a specific cell tropism in vivo and infect primarily the mature enterocytes of the villi 
of the small intestine. Entry of RVs into host cells is still poorly understood. Results from 
recent studies suggest that rotavirus cell entry involves a series of complex and coordinated 
events following proteolytic priming of the virus. The infectious virions (triple-layered particles 
TLPs) attach to the host cell through sialic acid containing receptors in the initial step. Next, 
interaction with integrins and Hsc70 occur during the subsequent post-attachment process 
(61). The spike-forming protein VP4 has essential functions in the virus life cycle, including 
receptor binding and cell penetration. The penetration of the plasma membrane is increased 
and most probably also dependent on trypsin treatment of the virus, which results in the 
specific cleavage of VP4 into VP8* and VP5* (62). This proteolytic cleavage enhances viral 
infectivity several fold (5). In the entry process, the VP8* domain is involved in the interaction 
with sialic acid-containing receptors, whereas VP5* is interacting with integrins. For some RV 
strains, involvement of sialic acid is not an essential step and viruses entering the cells in a 
sialic acid-independent manner are thought to mediate the entry step mainly by VP5* (18, 
52).  
The next step in the life cycle of RVs is the transcription of dsRNA segments into mRNA 
molecules that can be processed for viral protein production and template generation. 
Replication takes place exclusively in the cytoplasm. During the entry process, the outer 
capsid shell of the TLPs is removed by cellular enzymes and a low intracellular Ca2+ level 
resulting in double-layered particles (DLPs). The DLPs are the transcriptionally active form 
and large numbers of positive-stranded RNA molecules (5’ capped but not polyadenylated) 
are transcribed from all of the 11 RNA segments, which exit the DLPs via the 12 aqueous 
channels penetrating the VP2 and VP6 layers. The DLPs contain the full enzymatic 
machinery needed to synthesize the transcripts, to properly guanylate and methylate the cap 
structure of the mRNAs, and to facilitate the translation by the cellular translation machinery. 
VP1 is the RNA-dependent RNA polymerase (116) and VP3 is the guanylyl- and 
methyltransferase (13). The newly synthesized RNA molecules either act as mRNAs, leading 
to accumulation of the translated gene products in the cytoplasm, or undergo replication in 
intracytoplasmic inclusion bodies termed viroplasms. The two non-structural proteins NSP2 
and NSP5 are the major components of viroplasms and have been shown to be sufficient to 
form these electron-dense cytoplasmic inclusions (33, 64). The synthesis of dsRNA and the 
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packaging of the RNA molecules into pre-virion core particles are taking place in the 
viroplasms (109). Besides NSP2 and NSP5, the viroplasms also contain VP1, VP2, VP3, 
VP6 and NSP6 and in the beginning all the transcribed mRNA from all the genomic 
segments (6, 40). At present, the exact order of events during early morphogenesis and the 
control mechanisms by which the packaging of the RNA segments into the cores occur are 
unknown. The DLPs formed in the viroplasm consist of VP1, VP2, VP3 and VP6 and contain 
one of each of the 11 ds RNA segments. Again, how the correct set of 11 segments of ds 
RNA gets encapsidated into each virion remains entirely unclear. One model suggests that 
the genomes are packaged concurrent with the capsid assembly (93).  
Maturation and release are the final steps of the RV life cycle. Once the DLPs are formed, 
they bud from the viroplasms into the proximally located rough endoplasmic reticulum (rER) 
and receive a transiently rER-derived envelope layer, which is lost before complete 
maturation. During this step, the outer layer proteins VP4 and VP7 are incorporated. During 
budding of the DLPs through the rER, NSP4 acts as intracellular receptor for VP6 (7, 113). 
NSP4 and VP7 are both synthesized on the rER-associated ribosomes and co-translationally 
inserted into the ER membrane. Silencing the expression of NSP4 by siRNAs has been 
shown to block DLPs and TLPs, and the amount and distribution of the viral proteins was 
altered (63). Besides the role of NSP4 in viral morphogenesis, NSP4 is a viral enterotoxin 
capable of inducing diarrhea in mice on its own (8, 105) During the last step of RV 
morphogenesis, the transient lipid envelope is lost and the viral proteins are rearranged in 
order to form the outer layer consisting of VP7 and VP4, while NSP4 is excluded from the 
virus particle. The precise mechanism is not known, but the above mentioned siRNA 
experiments indicate that VP4 is assembled in the ER and VP7 is involved in the removal of 
the transient envelope (63). It was also reported that chaperones from the ER are involved in 
the quality control of the newly assembled virus particles (68).  
In non-polarized cells, electron microscopy studies have shown that progeny virus is 
released by lysis of the host cell (2). Late during infections, there are drastic alterations in the 
permeability of the plasma membrane observed resulting in the release of cellular and viral 
proteins (80). The polarized intestinal Caco-2 cells have been shown to spontaneously 
display many of the morphologic and biochemical properties of mature enterocytes. In these 
cells, RV was released almost exclusively at the apical pole of the cells, before any cells lysis 
was detected. The RV transport pathway from the ER to the apical surface of the intestinal 
cells is described as a non-conventional vesicular transport of virus particles from the ER to 
the apical plasma membrane that bypasses the Golgi apparatus and lysosomes (49). 
1.1.5 Current status of Rotavirus vaccines 
The burden of RV disease is high worldwide. According to the estimates based on studies 
done worldwide during 1986 – 2000, RVs cause 100 million episodes of acute 
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gastroenteritis, 25 million clinic visits, 2 million hospitalizations and approximately 600’000 
deaths per year (88, 89). The incidence of RV disease is similar for developed and 
developing countries, while deaths from RV infections are most frequent in developing 
countries of sub-Saharan Africa and Asia. RV-related deaths represent approximately 5% of 
all deaths in children younger than 5 years of age all over the world (27). Rates of RV illness 
in industrialized and less developed countries are similar, therefore, the supply of clean water 
and good hygiene have little effect on virus transmission. This highlights the urgent need for 
safe and effective RV vaccines, particularly in developing countries where timely healthcare 
is not always available and mortality because of RV infections is high (26). 
Human RVs show enormous diversity as the gene segments that encode the G (VP7) and P 
(VP4) proteins can segregate independently, giving rise to strains with at least 42 different P-
G serotype combinations (39). However, there are a small number of prevalent RV strains 
representing over 88% of the analyzed strains worldwide. The G and P serotypes also differ 
geographically, meaning that an effective vaccination program should take into account this 
geographical variation of the prevalent strains. Also monitoring the circulating strains after 
introduction of vaccine candidates may be necessary, as vaccine pressure may lead to the 
selection of novel RV strains.  
The first vaccine programs started in the early 1980s and these approaches were based on 
the “Jennerian” concept. This concept is using live attenuated animal RV strains (of simian or 
bovine origin) for the immunization of infants, as these strains are considered to be naturally 
attenuated in humans. None of these vaccine candidates however induced protection from 
severe RV disease, which led to the next generation of vaccines. Instead of using only one 
RV strain (monovalent vaccine), vaccines based on the “Modified Jennerian” approach, using 
human/animal RV reassortants, have been generated. This approach was based on the fact 
that RVs are able to reassort during double infections. These live reassortant virus vaccines 
contain some genes from the animal RV parent and some from the human RV parent. In 
general, the selected RV reassortants contained the VP7 gene derived from the human RV 
parent, as this protein was thought to be important for protection. The remaining genes were 
from the animal RV strain, giving a genome background of a non-pathogenic animal RV 
expressing the human P and G types. The first multivalent live oral reassortant vaccine 
developed was RotaShield, a rhesus rotavirus (RRV) tetravalent vaccine. It contained the 
VP7 gene derived from human RV strains belonging to the G types, G1, G2 and G4. As RRV 
belongs to the G3 type, this vaccine represented the four epidemiologically most important 
RV G serotypes. Protective efficacy of this vaccine against severe RV disease was 70 to 
100% in large field trials; therefore, it was recommended for universal immunizations in the 
US and licensed in 1998. After vaccinating over 600’000 children in the US, several cases of 
vaccine-associated intussusception (the invagination of the intestine into a distal segment) 
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were reported and its manufacturers immediately withdrew Rotashield from the market. 
Initially, VP7 was thought to be the most important antigen in inducing protection, but more 
recently, also VP4 was considered to be important for protection. Therefore, human-animal 
reassortant RV vaccine candidates now include either human VP7 or VP4 genes (10, 26, 27, 
92, 108). 
 
Currently licensed RV vaccines. (4, 28, 120). The first RV vaccine after the withdrawal of 
RotaShield in 1999 was licensed in Mexico in 2004. This attenuated human vaccine Rotarix 
became available in January 2005 and was produced by GlaxoSmithKline. Since then, this 
vaccine has been licensed in nearly 100 countries, including European countries. The 
monovalent (contains a single human RV strain) vaccine is derived from a human RV isolate 
and attenuated by multiple passages in tissue culture. This vaccine was generated on the 
assumption that one natural RV infection in children prevents a second severe infection. 
Rotarix was evaluated in several studies and found to be highly efficient (85%) in preventing 
severe RV gastroenteritis and hospitalizations. Because of the association of RotaShield with 
intussusception, the next vaccines had to undergo large safety trials. Rotarix was evaluated 
in a study with over 63’000 infants and shown to be safe and, most importantly, not 
associated with intussusception (97). In 2006, the pentavalent reassortant vaccine Rotateq, 
developed by Merck, was licensed, first in the USA and subsequently also in the European 
Union. This RV vaccine is based on the attenuated bovine RV strain WC3. It consists of a 
mixture of five mono-reassortant strains, each of which contains a gene encoding for VP4 or 
VP7 from a RV of human origin, but the other segments in all mono-reassortants are 
provided by the bovine WC3 strain. Therefore, this vaccine was generated to contain most of 
the different serotypes that a child will be exposed to in the assumption that this is the most 
effective approach to induce broad protective immunity. Also this RV vaccine underwent 
large safety trials, and it was found to be highly effective in preventing severe RV 
gastroenteritis (98%), and no link with intussusception was found.  
In Switzerland, vaccination against RV is not included in the national vaccination schedule, 
as there are not many deaths caused by RV infections (BAG and EKIF 2008) and the 
disease is efficiently treated by rehydration. Nevertheless, Rotarix is licensed in Switzerland. 
There are an estimated 6200 doctoral visits and 500-1000 hospitalizations due to RV disease 
reported each year in Switzerland, but the vaccines are too expensive (approx 216 CHF) 
relative to the expected benefit. 
 
Alternative RV vaccine candidates 
All currently licensed RV vaccines are live, orally administered vaccines that aim to mimic the 
protection given by naturally occurring RV infections, and all RV vaccines tested in children 
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have been either live viral vaccines of a Jennerian or modified Jennerian approach or 
attenuated human RVs. 
The original expectation for a successful RV vaccine was that it should protect against 
almost all cases of RV disease of any severity. After realizing that even natural infections 
with RV do not provide complete protection against subsequent RV illnesses, a more realistic 
goal for a RV vaccine would be that it provides a high level of protection against severe RV 
diseases. The currently licensed vaccines realized this goal so far, however, none of the 
efficacy trials have been completed in the Third World nations where deaths because of RV 
infections are most common and where the earlier RV vaccine candidates failed to provide 
significant protection. Together with not fully resolved safety concerns associated with live 
vaccines, non-living RV vaccine candidates are developed as possible next generation 
vaccines. These candidates range from fully intact, inactivated RVs to pieces of RV proteins 
and even DNA vaccines. However, three types of these next generation vaccine candidates 
are most promising. These include inactivated triple- and double-layered RV particles, triple- 
and double-layered virus-like particles (VLPs) and recombinant, E.coli-expressed VP6 
proteins. Since the 1980s, these vaccine candidates are being tested in animal models, but 
until now, none have been evaluated in humans, not even in phase 1 trials (119). 
 
Inactivated virus. Viral particles are inactivated by physical or chemical methods and 
delivered by either parenteral or mucosal (intranasal) routes. This approach was tested in 
mice (75, 76), rabbits (19) and gnotobiotic piglets (114, 126) and found to be effective in 
reducing or preventing RV shedding with or without the use of adjuvants. Parenteral 
immunization with formalin-inactivated RV strain RRV combined with lipid adjuvants was 
evaluated in the infant mouse model and showed to protect the offspring from clinical 
diarrhea upon challenge (47). 
 
Virus-like particles (VLPs). Production of RV VLPs was first reported in the 1980s (20, 32, 
94). There are many expression vectors to produce the recombinant proteins for VLPs 
formation, but the well-established baculovirus system is the most common expression 
vector used and also facilitated the analysis of virus structure and, to some extent, of virus 
assembly. Core, double- and even triple-layered VLPs have been produced in insect cells 
infected with baculovirus vectors (20, 29, 55). However, the limitations of the baculovirus 
system include the inefficient infection of mammalian cells and, consequently, the need to 
purify VLPs from infected insect cells for vaccination. Insect cells may not be suitable to 
study virus assembly either, because the posttranslational processing of proteins in insect 
cells greatly differs from that in mammalian cells (54, 79). Therefore, viral vectors that can 
infect mammalian cells, including Semliki Forest virus based replicons (81) and vaccinia virus 
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vectors (41), have also been evaluated for the generation of rotavirus VLPs. Some VLPs 
contain only VP2 and VP6, while others have incorporated one or more of the neutralization 
proteins VP4 or VP7; some VLPs are also composed of the full set of the structural proteins. 
The use of a VLP prime (VLPs containing VP2 and VP6) and recombinant adenovirus 
expressing VP6 boost regimen were found to elicit stronger humoral, mucosal and cellular 
immune responses and confer stronger protection against RV challenge than each of the 
VLPs alone (128). The effect of maternal antibodies on different routes of administration was 
investigated using non-replicating RV VLPs of bovine origin composed of VP2, VP6, VP7 
and VP8* fused to VP2 and both, parenteral and oral immunization of newborn mice resulted 
in specific serum IgG response (48).  
 
E.coli-expressed VP6 proteins. As VLPs composed of only VP2 and VP6 provided 
excellent protection against RV shedding when they have been administered intranasally 
with a powerful adjuvant (84), it was possible that the VP6 protein alone could stimulate 
protection against RV shedding. Therefore, E.coli-expressed VP6 proteins from murine or 
human RV strains have been tested in mice. They were orally, intrarectally or intranasally 
administered together with effective adjuvants and found to effectively protect mice against 
fecal RV shedding (17). In another approach, VP6 was expressed in E.coli as a fusion 
protein with maltose binding protein and administered intranasally to mice together with a 
potent adjuvant. After challenge, the mice were protected nearly 100% from fecal shedding 
of RV (15, 16). VP6 is the group antigen and therefore highly conserved in group A RVs, thus 
it is not surprising that protection of mice immunized with VP6 from a human strain was 
highly effective when mice were challenged with heterotypic murine RVs. 
 
Is there need for another RV vaccine?  
Taken together, several drawbacks have affected the development and application of the RV 
vaccines: (i) In general, RV vaccines have performed better in developed than in non 
developed countries, probably due to inhibition by higher natural exposition before 
vaccination, or atypical serotypes prevalence in less developed countries (10). (ii) The 
withdrawal of RotaShield because of the observed association with intussusception resulted 
in extended testing and delays in the licensure of the next vaccine candidates. (iii) Another 
difficulty is the rapid generation of the specific reassortants, making it complicated to adapt 
the vaccine for use in regions where the dominant serotype is not included in the original 
formulation (i.e. G5 in Brazil, G9 in Argentina, etc). (iv) At least three doses are necessary to 
reach adequate protection against all the included serotypes, which makes vaccination 
difficult, expensive, or impracticable. Also the young age of administration because of the 
strict safety settings from the clinical trials will be extremely difficult to achieve in developing 
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countries. (v) The oral delivery implies that special buffer and stabilization components 
should be added to the formulation in order to avoid inactivation by the stomach milieu. (vi) 
One main concern is based on the constant and rapid evolution of RV, due both to their RNA 
genome and to the fact that their genes can reassort between strains co-infecting the same 
host. This fact is an important threat to the rational of using live attenuated rotavirus strains 
as vaccines, both because these strains can revert to more virulent phenotypes and because 
these vaccine strains are being released to the nature in the faeces of the inoculated 
persons, raising a considerable ecological concern (51).  
1.2 Herpesviruses 
Herpesviruses are highly disseminated in nature and most animal species have yielded at 
least one herpesvirus upon examination (90). The word herpes means to creep or crawl, in 
reference to the spreading nature of the visualized skin lesions that have been documented 
since ancient Greek times. The membership in the family Herpesviridae is based on the 
architecture of the virion. A typical herpesvirion consists of a core containing a linear double-
stranded DNA, an icosadeltahedral capsid of approximately 100-110 nm in diameter, the 
tegument that surrounds the capsid, and an envelope containing viral glycoprotein spikes on 
its surface (Figure 3). The family contains more than 130 members with a host range from 
mammals and birds to amphibians and reptiles.  
Glycoproteins
Lipid envelope
Portal vertex
Viral DNA
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Tegument
 
Figure 3: HSV-1 virion structure. The major structural components of the HSV-1 virion are: the viral dsDNA 
packaged in an icosahedral capsid, the tegument layer containing multiple viral proteins and the lipid membrane 
envelope studded with viral glycoproteins. On the right: electron micrograph (Negative contrast, E. Schraner 
University of Zurich). Schematic of a HSV-1 virion is shown on the left (Adapted from ViralZone: 
www.expasy.org/viralzone, Swiss Institute of Bioinformatics). 
The known herpesviruses appear to share four significant biologic properties (90): (1) All 
herpesviruses specify a large array of enzymes involved in nucleic acid metabolism, DNA 
synthesis and processing of proteins, although the exact array of enzymes may vary from 
one herpesvirus to another. (2) The synthesis of viral DNAs and capsid assembly occurs in 
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the nucleus and capsids are enveloped as they transit through the nuclear membrane. (3) 
Production of infectious progeny virus is invariably accompanied by the destruction of the 
infected cell, but the infected host is in general not killed. (4) The herpesviruses examined to 
date are able to remain latent in their natural hosts. Latency occurs in the natural host and in 
specific cell types, and many herpesviruses have specific genes required for the 
establishment of latency. In the latent state, the viral genome is present as a circular 
episome that replicates along with the DNA of the host cell and only a small subset of viral 
genes are expressed, and there is no production of infectious virus. Latent genomes retain 
the capacity to replicate and cause disease upon reactivation that is dictated by the 
environment of the host cell. The precise mechanisms that lead to reactivation from the latent 
state are not fully understood and may differ from one virus to another. Herpesviruses also 
differ with respect to their biologic properties. Some have a wide host-cell range, multiply 
efficiently and rapidly destroy the cells they infect. Others have a narrow host cell range or 
have a long replicative cycle. The members of the family Herpesviridae were classified into 
three subfamilies on the basis of biologic properties and before DNA sequences of the 
individual members were known: α-, β- and γ-Herpesvirinae. The members of the subfamily 
Alphaherpesvirinae were classified on the basis of a variable host range, relatively short 
reproductive cycle, rapid spread in culture, efficient destruction of infected cells and the 
ability to establish latent infections primarily but not exclusively in sensory ganglia. This 
subfamily contains the genera Simplexvirus (HSV-1), Varicellovirus (VZV), Mardivirus and 
Iltovirus. The first two genera have mammalian hosts, whereas the latter two have avian 
hosts (90). 
1.2.1 Life cycle of herpes viruses 
To initiate infection, the virus must attach to cell surface receptors. This initial attachment 
rapidly follows the transmission of the virus through the plasma membrane. The de-
enveloped tegument-capsid structure is then transported to the nuclear pores, where DNA is 
released into the nucleus. Transcription of the viral genome, replication of viral DNA and 
assembly of new capsids take place in the nucleus, whereas all viral proteins are 
synthesized in the cytoplasm. During productive infection, the viral proteins are expressed in 
a highly regulated cascade fashion in a number of co-ordinately expressed groups of gene 
products, and several proteins play a role in regulation of viral gene expression. The host 
RNA polymerase II is responsible for transcription of all viral genes during infection, although 
viral gene products may modify its activity and structure. Virus entry is followed by 
immediate-early and early gene expression. Several of the early gene products are enzymes 
and DNA-binding proteins involved in viral DNA replication. The bulk of viral DNA is 
synthesized by a rolling-circle mechanism, yielding concatemers, which are cleaved into 
monomers during the process of capsid assembly. The viral proteins involved in replication of 
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the viral DNA and nucleotide metabolism promote viral DNA replication, which in turn 
stimulates the expression of late, genes. The ultimate goal of viral late gene expression is to 
produce large amounts of viral structural proteins for assembly of progeny viral particles. 
Viral capsid assembly occurs in the infected cell nucleus and, after encapsidation of full-
length viral genomic DNA molecules, the virus matures, acquires infectivity and is now able 
to spread from one cell to another.  
1.2.2 Herpes simplex virus type 1 
Herpes simplex virus type 1 (HSV-1) is a common human pathogen causing infections of 
orofacial mucosal surfaces. Productive infections lead to the formation of vesicular lesions in 
the mucosal epithelia, which is followed by spread of the virus to sensory neurons and 
establishment of a latent infection. This latent state may remain for the lifetime of the infected 
host and reactivation of lytic infection results in recurrent disease at or adjacent to the site of 
the primary infection. The cold sores caused by HSV-1 are not life-threatening, but the virus 
can infect the central nervous system, leading to serious diseases like keratitis and 
encephalitis (121). The virus can efficiently infect a wide variety of cells, including dividing 
and non-dividing cells. 
HSV-1 is a large (150-200 nm in diameter) enveloped virus composed of three different 
compartments, an icosahedral capsid containing the dsDNA genome, the tegument that 
contains additional viral proteins and an envelope of host origin equipped with viral 
glycoproteins (Figure 1). The genome is composed of 152 kb linear double-stranded DNA 
encoding at least 80 genes (Figure 5). Two covalently linked segments are forming the 
genome, both segments contain unique regions (unique long UL and unique short US) each 
flanked by inverted repeats (terminal and internal). HSV-1 contains three lytic origins of 
replication, named depending on their location, oriL or oriS, and two DNA packaging signals, 
pac, which ensure proper cleavage and packaging of unit-length progeny genomes (25, 95). 
The understanding of the biological properties of HSV-1 and the molecular mechanisms of 
virus replication has allowed the development of potential vectors for several applications in 
human healthcare, including delivery and expression of human genes to cells of the nervous 
system, selective destruction of cancer cells, prophylaxis against infections of HSV or other 
infectious diseases and targeted infections of specific tissues or organs. Three different types 
of vectors can be derived from HSV-1: (1) Replication-competent attenuated vectors carrying 
mutations, which restrict spread and lytic viral replication to the specific target cells. These 
vectors are being used mainly as oncolytic viruses. (2) Replication-incompetent defective 
recombinant vectors, which either lack or are deleted for one or more genes essential for in 
vitro virus replication. (3) Defective helper-dependent vectors known as amplicons, which 
carry no viral genes and take advantage of the large transgene capacity of the HSV-1 
particle (23, 67, 112). 
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1.2.3 HSV-1 amplicon vectors 
HSV-1 amplicon vectors originated about 30 years ago when Spaete and Frenkel (110) 
analyzed the nature of defective virus genomes generated during passage of standard HSV-
1 stocks at high multiplicity of infection. Their investigations revealed that an origin of 
replication and a cleavage/packaging signal, pac, were the only two cis-acting sequences 
required for the replication and packaging of defective virus genomes in the presence of 
trans-acting HSV-1 helper virus (111). 
Amplicon vectors are HSV-1 particles identical to wild-type HSV-1 from the structural, 
immunological and host-range points of view, but instead of the viral genome, they carry a 
DNA plasmid in a concatemeric form, named the amplicons plasmid. The HSV-1 amplicon 
particles are composed of approximately 40 different virus-encoded structural proteins, which 
are delivered into the cell during infection. Therefore, they can trigger cell signalling and 
cellular responses and may have a transient impact on cell homeostasis or gene expression, 
but these proteins will soon disappear and the cells retain their normal functions (21, 115).   
 
Figure 4: Basic HSV-1 amplicon plasmid. The two non-coding 
elements of HSV-1, the origin of replication oris and the 
packaging/cleaving signal pac allow replication of amplicon DNA 
and packaging into HSV-1 virions. For the propagation in E.coli, 
the plasmid contains an origin of replication (colE1) and the 
antibiotic resistance gene (ampr). The transgene cassette 
usually contains a fluorescent marker to titrate the amplicon 
vector stocks.  
Current HSV-1 amplicon plasmids are standard E.coli plasmids carrying typically two non-
coding elements of HSV, oris and pac; a bacterial origin of replication and an antibiotic-
resistance gene for propagation in E.coli; a fluorescence marker gene and the transgene 
expression cassette with the gene(s) of interest (Figure 4). Amplicons can easily be 
constructed by recombinant DNA technologies, shuttled between prokaryotic and eukaryotic 
cells and packaged in different cell lines as a single amplicons of up to 150 kb or as 
concatenates with multiple copies of the transgene cassette into HSV-1 virions (85) due to 
the rolling circle mode of HSV-1 DNA replication and the genome packaging capacity of the 
HSV-1 capsid (~150 kb). This results in very high levels of gene expression (106). One major 
advantage of the amplicons vectors as gene transfer tools is the fact that they do not carry 
viral genes and consequently do not induce synthesis of HSV-1 proteins. Therefore, these 
vectors are entirely non-toxic for the infected cells and non-pathogenic for the transduced 
organism; reactivation, complementation or recombination with latent or resident HSV-1 
genomes is strongly reduced, especially when amplicon vectors are generated using a 
helper-virus free system (99). HSV-1 amplicons do not express any viral genes but depend 
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on helper functions for replication and packaging into HSV-1 virions. For the production of 
amplicon vector stocks, essential HSV-1 functions are supplied in trans by a viral genome or 
a helper virus. Currently, two trans-complementing systems are used, based either on cloned 
HSV-1 DNA or on helper HSV-1. Both systems can generate contaminating helper HSV-1 
particles, which are toxic for the cells and can induce inflammation, which is the main 
concern to use these vectors in gene therapy (21). 
 
Helper virus-dependent production of HSV-1 amplicon vectors 
The helper virus-assisted packaging system developed by Epstein and co-workers is a two-
step process with an initial co-replication and packaging of helper virus and amplicon 
plasmids. The packaging signal of the helper virus is deleted by Cre/loxP-based site-specific 
recombination, allowing preferential packaging of the amplicon DNA, which contains the pac 
signal. The helper virus contains a single pac signal flanked by two loxP sites in parallel 
orientations and a deletion of the two genes surrounding the pac signal, encoding a virulence 
factor ICP34.5 and the essential protein ICP4. The amplicon vector stocks are produced in a 
first step in ICP4-complementing cells transfected with the amplicon plasmids and infected 
with helper virus, resulting in a mixture of amplicon vectors and helper virus. In a second 
step, this mixed stock is used to infect ICP4 and Cre-expressing cells, where Cre 
recombinase mediates the excision of the pac signal from the helper genome, inhibiting 
helper virus packaging. With this system, large vector stocks can be prepared, containing 
around 0.05 to 0.5% of contaminating helper virus. As ICP4 is deleted in the helper genome, 
this helper virus cannot replicate in non-complementing cells (21, 60). Nevertheless, the 
contamination with helper virus, although defective, may be toxic to sensitive cells, and may 
evoke an immune response to transduced cells; recombination with endogenous HSV-1 may 
also occur.  
 
Helper virus-free packaging of HSV-1 amplicon vectors 
Helper virus-free packaging of amplicon vectors has undergone continuing improvement 
(Figure 5). The initial system was based on transfection of a set of five overlapping cosmids 
encoding the entire HSV-1 genome to provide the necessary functions for the replication and 
packaging of amplicon DNA into HSV-1 particles. The packaging of the HSV-1 genome itself 
was blocked by deletion of the DNA cleavage/packaging (pac) signals from the cosmids (22, 
36). Limitations to this amplicon packaging include (i) the genetic instability of the cosmid 
clones, (ii) complicated procedure in preparing five HSV-1 DNA fragments from cosmids and 
(iii) difficulty in large scale production of vector stocks (106). To overcome the first two 
problems, the entire pac-deleted HSV-1 genome was subcloned into a single-copy F-
plasmid-based bacterial artificial chromosome (BAC), fHSV∆pac (100). This BAC-based 
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packaging system achieves several improvements over the cosmid-based version, including 
(i) genetic stability of the helper HSV-1 genome in E.coli, (ii) a simplified packaging 
procedure and (iii) increased amplicon vector titers. There was still the possibility of a 
homologous recombination event between the oris sequences present on both fHSV∆pac 
and amplicon, thus allowing reintroduction of pac into the helper genome resulting in 
contamination of the vector stocks with replication-competent helper virus. Virtual elimination 
of contaminating replication-competent helper virus has now been achieved by deleting an 
essential HSV-1 gene, ICP27, from fHSV∆pac and providing ICP27 in trans from another 
plasmid (98, 99).  
 
 
Figure 5: Helper virus-free packaging system. (A) The HSV-1 genome is formed of two covalently linked 
segments, both segments contain unique regions (unique long UL and unique short US) each flanked by inverted 
repeats (terminal TR and internal IR). HSV-1 contains three lytic origins of replication, named depending on their 
location, oriL or oriS, and two DNA packaging signals (pac) (B) Schematic diagram of HSV-1 cosmid set with 
deleted (X) packaging signals (pac). (C) Schematic diagram of HSV-1 helper BAC DNA. This plasmid contains all 
the trans-acting functions required for replication and packaging of the amplicon DNA, but lacks the cis-acting 
elements required for its own packaging (pac signals) and the ICP27 to eliminate possible recombination. (D) 
DNA based method for amplicon vector production. Co-transfection of permissive cells with amplicon plasmid and 
either cosmid DNA (left) or BAC DNA and ICP27-expressing plasmid results in helper virus-free amplicon stocks. 
(From Current Protocols in Neuroscience 2007; with permission (35)) 
The current packaging system is based on this oversized pac- and ICP27 deleted HSV-1 
genome cloned as a BAC (fHSV∆pac∆27). This system requires co-transfection of amplicon 
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DNA and the HSV-1 helper DNA into permissive cells, the VERO 2-2 cell line (Figure 5). This 
cell line is stably transfected with the ICP27 gene. Complementation of the ICP27 gene is 
further achieved by co-transfection of the cells with an ICP27-expressing plasmid. Using this 
helper BAC, fHSV∆pac∆27, with the deletion in ICP27, amplicon vectors are packaged 
without detection of replication-competent virus and are therefore entirely helper virus-free. 
However, the amount of total amplicon vectors produced by this method is limited, as these 
vector stocks cannot be further amplified. Another reason why the helper virus-free system 
results in lower vector titers may be due to viral tegument proteins which are present in the 
helper virus and are known to prime the cell for virus production via the trans-activation of 
immediate early genes (VP16) or by regulating cellular and viral transcription (vhs) (24). 
However, further optimization and refinement of the currently used helper virus-free systems 
will be required to achieve titers high enough for clinical testing of the amplicons vectors.  
1.2.4 HSV-1 amplicons as vaccine vectors 
Infection with wild-type HSV-1 results in a potent host immune response involving both, the 
innate and the adaptive immune system (53), but the virus is also able to evade the host 
immunity through a variety of mechanisms based upon immuno-modulatory gene products 
such as the virion host shutt-off protein, vhs (102), or the ICP47 protein (125). HSV-1 
amplicon vectors are very promising candidates for vaccine delivery because they retain the 
strong inherent immunogenicity of the parental virus, while eliminating many of the unwanted 
viral functions for immune evasion. Other characteristics of the amplicon vectors include their 
safety, large transgene capacity and the wide host range. 
It has been demonstrated in a number of studies, that HSV-1 amplicon vectors are able to 
transduce antigen-presenting cells (APC) without impairing their antigen-presenting 
functions. Using helper virus-free amplicons, it was shown that about 70% of bone marrow 
derived murine dendritic cells (DC) were transduced without loss of function (122). Two other 
groups documented efficient expression of model transgenes by transduced DCs without 
impairment of the antigen-presenting function (42, 83), which is an important task for the use 
of amplicons vectors as vaccines. Most studies focused on the immunization against HIV. 
One group showed that a single dose of 1x106 transducing units of amplicon vectors 
expressing the HIV envelope glycoprotein gp120 was able to elicit strong, antigen-specific 
and long-lasting cellular and humoral responses in mice (44). Subsequent work showed that 
amplicon-induced immune responses could strongly be enhanced by prior priming with either 
a DNA vaccine encoding the same antigen or by an initial prime with the amplicon vectors 
(118). Taken together, amplicon vectors have shown promising results as vaccine delivery 
system in several preclinical systems, including animal models for cancer treatment and 
prophylactic immunizations against infectious pathogens (HIV-1). Another often discussed 
difficulty is the effect of pre-existing immunity on HSV-1 mediated gene transfer, as HSV-1 is 
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an ubiquitous virus in the human population and, thus, anti-HSV-1 antibodies are present in 
most adults. This may interfere with amplicon-mediated vaccination, as these could lead to a 
direct vector neutralization or rapid clearance of the amplicon-transduced cells. There is one 
study where the investigators used a heterologous HSV-1 strain to generate an anti-HSV-1 
immune response in mice, which were subsequently immunized via the subcutaneous route 
using helper virus-free amplicons vectors. The mice showed significant titers of neutralizing 
antibodies, but this resulted in only a modest reduction in the amplicon-induced cellular 
response (44). These data suggest that the pre-existing immunity in hosts may not prevent 
the successful use of amplicon-based vaccines. 
1.3 Virus-like particles 
The structural proteins of many viruses have the ability to self-assemble spontaneously into 
particles that are similar to the authentic viruses. These virus-like particles (VLPs) are non-
replicative and non-pathogenic because they assemble without incorporating genetic 
material, thus they do not contain any viral genome. The term “virus-like” refers to the 
morphological similarity of the VLP to the corresponding virion. Depending on the complexity 
of the virus, VLPs can be produced from one or several structural proteins being in the 
general size range of the parent virus, with their exact size and morphology depending on 
the particular viral proteins they are made of (82). VLPs are structurally stable and can be 
manipulated to carry and display heterologous molecules. Multiple capsid proteins may be 
assembled either from expression and subsequent processing of a precursor protein or by 
co-expression of the capsid proteins from multicistronic vectors in the same cell (117). There 
are many expression systems for the production of VLPs, including (i) various mammalian 
cell lines, either transiently or stably transfected or transduced with viral expression vectors 
(74, 103, 123); (ii) the baculovirus/insect cell system (37, 45, 129); (iii) various species of 
yeast (38, 71, 104) and (iv) Escherichia coli and other bacteria (59, 78, 124). The choice of 
the production system depends on the type of VLPs to be produced and the number of 
different structural proteins the VLPs are made of. Mammalian cell culture systems are 
favoured because they support appropriate modifications and authentic assembly, but are 
less controllable and more costly for production, whereas the E.coli system may be efficient, 
but often there are additional steps required for the assembly (14). Clearly, not all VLPs 
generated to date are used as vaccines, some have been generated to understand the 
assembly process, study the morphogenesis or the architecture of the viruses.  
 
Virus-like particles for vaccination 
The most potent vaccines used in the past are attenuated or inactivated forms of whole 
viruses, but there always remains the risk of reversion into the pathogenic virus. VLPs on the 
other hand are safe as they do not contain infectious genetic material. Safety is the most 
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important requirement for vaccines today, especially when they are used for prophylaxis. 
Therefore, it is crucial to generate vaccines that are safe but at the same time able to induce 
potent and long-lasting immune responses. VLPs offer a promising approach to the 
production of vaccines against many diseases, because they contain well-exposed, repetitive 
domains on their surfaces, leading to the display of highly ordered or even conformational 
epitopes, which is often effective in eliciting strong immune responses (43, 107). VLPs are 
generally more immunogenic than subunit or recombinant protein immunogens, do not need 
immune stimulating adjuvants and are able to stimulate both the humoral and cellular arms of 
the immune system, including neutralizing antibodies (91, 96). The fact that VLPs are closely 
similar to the equivalent virus made them most promising candidates for the development of 
vaccines against the corresponding virus. A wide variety of VLPs have shown promising 
results in small animal models and may offer great potential for the development of vaccines. 
To date, two vaccines for humans based on VLPs are licensed, the papilloma virus vaccine 
and the hepatitis B virus vaccine (46, 73). Several vaccines based on VLPs are in 
development and in clinical trials, including vaccines against hepatitis C, malaria, SARS, 
Ebola, Marburg virus, Rift Valley fever, influenza, Norwalk virus, HIV and rotavirus (43, 86). 
However, there is a major limiting factor to overcome for the successful introduction of more 
VLPs-based vaccines, this are the high production and purification costs to obtain the large 
amount of highly purified particles needed for large clinical trials. Vaccination using VLPs is 
costly compared with other vaccines, which makes it difficult to perform clinical trials. 
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2 Results 
2.1 Results Part I: Rotavirus 
2.1.1 HEVAR 
Herpes virus-based vaccines against rotavirus infections (HEVAR) is a collaborating 
European project involving laboratories from Europe and South America. The overall 
scientific goal of HEVAR was to contribute to a better understanding of the immune biology 
of rotavirus infections using a novel generation of gene transfer vectors derived from herpes 
simplex virus type 1 (HSV-1).  
One goal of this project was to construct HSV-1 based vaccine vectors expressing the 
structural genes of rotavirus using the helper virus-free HSV-1 based amplicon vector 
system. These antigens are expressed either individually or in different combinations, 
allowing in the most complex case the in situ generation of empty rotavirus like particles 
(VLPs) inside the vector-vaccinated organisms. Furthermore, the capability of these vectors 
to elicit protective immune responses is tested in mice. 
2.1.2 Aim of the project 
Rotaviruses are the cause of life-threatening gastroenteritis in children worldwide, thus this 
global and enormous disease burden has led to the effort to develop safe and effective 
vaccines.  
The goal of this thesis was to construct and evaluate HSV-1 amplicon vectors encoding 
individual or multiple structural rotavirus proteins from a polycistronic transgene cassette. In 
this particular case, the amplicon vectors express two or three structural genes forming the 
double- or triple-layered capsid of the rotavirus, respectively. The capability of the vectors to 
support the in situ production of rotavirus-like particles in vector-infected mammalian cells is 
demonstrated. Furthermore, the potential usefulness of these amplicon vectors for 
vaccination is evaluated by assessing their ability to induce specific antibody responses in 
vector-vaccinated mice and to protect from disease upon challenge with wild-type rotavirus. 
2.1.3 Manuscript Rotavirus 
 
Own contribution to the manuscript: 
Construction and characterization of HSV-1 amplicon vectors (IF and WB) 
Production of vector stocks for immunization of mice 
Characterization of VLPs by electron microscopy (assistance from E. Schraner) 
Analysis of VP6 splicing 
Writing of the manuscript 
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Manuscript Rotavirus 
 
 
Abstract 
 
Virus-like particles (VLPs) are promising vaccine candidates because they represent viral 
antigens in the authentic conformation of the virion and are therefore readily recognized by 
the immune system. As VLPs do not contain genetic material they are safer than vaccines 
produced with attenuated viruses. In this study, herpes simplex virus type 1 (HSV-1) 
amplicon vectors were constructed to co-express the rotavirus (RV) structural genes VP2, 
VP6, and VP7 and were used as platforms to launch the in situ production of rotavirus-like 
particles (RVLPs) in vector infected cells. We demonstrate that these vectors indeed 
supported the efficient production of RVLPs in infected mammalian cells. Intramuscular 
injection of mice with the amplicon vectors as a two-dose regimen without adjuvants resulted 
in detectable humoral immune responses. Moreover, partial protection was observed in 
immunized mice challenged with wild type RV strain EC, as shown by significantly reduced 
shedding of RV antigen in stool. This work provides proof of principle for the potential 
usefulness of the HSV-1 amplicon vectored production of RVLPs as genetic vaccine. 
Andrea Laimbacher PhD Thesis Results 
 34 
Introduction 
 
Rotaviruses (RVs) are segmented, double-stranded (ds) RNA viruses of the Reoviridae 
family and are the most common cause of acute viral gastroenteritis in infants and young 
animals around the world. Almost all children both in developing and developed countries are 
infected with RVs during their first years of life and even advanced levels of sanitation and 
hygiene appear unable to control the spread of RV infections. Death from RV infection is 
most prevalent in developing countries where timely health care is not always available, 
causing more than 600,000 deaths per year (17, 101). Although the recently licensed human 
RV vaccines, which are based on orally administrated live attenuated strains, are very 
successful, data from clinical trials and post-licensure studies indicate that both vaccines are 
significantly less effective in low-income countries of Africa, Asia and Latin America (73, 77, 
97). Additionally, potential safety issues like the risk of intussusception, inadvertent 
immunization of immunosupressed individuals and generation of new pathogenic strains by 
reassortment of vaccine strains with wild-type human and animal RV, suggest that 
development of new RV vaccines is still needed. Owned to the history of lower efficacy of all 
live oral vaccines in low-income countries, alternative approaches like parenteral vaccines 
should be pursued (44). Among these, inactivated RV particles, VLPs, subunit and vector 
based vaccines have been tested in animal models (9, 47, 108). 
Mature infectious RV particles are non-enveloped, triple-layered icosahedral capsids. The 
innermost layer, composed of VP2 protein, encloses the 11 genomic segments of dsRNA. 
The middle layer is composed of the major capsid protein VP6, and the outermost layer is 
made of the glycoprotein VP7 and spikes of VP4. Both outer proteins are targets for 
neutralizing antibodies and define the virus G and P serotypes (38). Although a component 
of the middle layer in the mature particle, VP6 elicits a strong humoral immune response, 
and at least one strong T-cell epitope has been mapped which is highly conserved in most 
group A RV strains (2). The viral genome encodes six structural proteins (VP1 to VP4, VP6, 
VP7) and, depending on the viral strain, five to six nonstructural proteins (NSP1 to NSP6) 
(22).  
The structural proteins of many viruses have the ability to assemble spontaneously into 
particles that are similar to the authentic viruses. These virus-like particles (VLPs) are in the 
general size range of viruses, with their exact size and morphology depending on the 
particular viral proteins they are made of (69). Importantly, VLPs are replication-defective 
because they assemble without incorporating genetic material. VLPs offer a promising 
approach to the production of vaccines against many diseases, because their repetitive, high 
density display of epitopes is often effective in eliciting strong immune responses (34, 89). 
VLPs are generally more immunogenic than subunit or recombinant protein immunogens and 
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are able to stimulate both the humoral and cellular arms of the immune system (74, 76). 
VLPs provide the spatial structure for display of conformational epitopes and, in doing so, are 
most likely to mimic the native virus structure, thereby enhancing the production of 
neutralizing antibodies. A wide variety of VLPs have shown promising results when applied in 
small animal models and may offer great potential for the development of vaccines (34). To 
date, two VLP-based vaccines are licensed for application in humans, the papilloma virus 
vaccine and the hepatitis B virus vaccine (42, 62). 
Multiple capsid proteins may be assembled either from expression and subsequent 
processing of a precursor protein or by co-expression of the capsid proteins from 
multicistronic vectors in the same cell (98). There are many expression systems for the 
production of VLPs, including (i) various mammalian cell lines, either transiently or stably 
transfected or transduced with viral expression vectors (63, 82, 102); (ii) the 
baculovirus/insect cell system (27, 41, 109); (iii) various species of yeast (29, 61, 85) and (iv) 
Escherichia coli and other bacteria (55, 65, 105). Mammalian cell culture systems are 
favored because they support appropriate modifications and authentic assembly, but are less 
controllable and more costly for production.  
The expression of RV proteins using the well established baculovirus system facilitated the 
analysis of virus structure and, to some extent, of virus assembly. Core, double- and even 
triple-layered RV-like particles (RVLP) have been produced in insect cells infected with 
baculovirus vectors (13, 20, 52). However, the limitations of the baculovirus system include 
the inefficient infection of mammalian cells and, consequently, the need to purify RVLPs from 
infected insect cells for vaccination. Also, insect cells may not be suitable to study virus 
assembly, because the posttranslational processing of proteins in insect cells greatly differs 
from that in mammalian cells (51, 67). Therefore, viral vectors that can infect mammalian 
cells, including Semliki Forest virus based replicons (68) and vaccinia virus vectors (30) have 
also been evaluated for the generation of RVLPs.  
Herpes simplex virus type 1 (HSV-1) based vectors are being evaluated for gene therapy 
applications (7, 14, 37, 60, 71, 80) and are also considered promising vehicles to deliver 
antigens and immune-modulators for prophylactic and therapeutic vaccination, as well as for 
fundamental research (5, 14, 16, 43, 50). Specifically, HSV-1 amplicon vectors have a large 
transgene capacity (up to 150 kb), which allows the delivery of multiple transgenes or 
multiple copies of a single transgene. Additional advantages of HSV-1 amplicon vectors 
include (i) low toxicity and low immunogenicity, in particular when helper virus-free packaging 
systems are used (79, 88), (ii) high transduction efficiencies in dividing and non-dividing cells 
from most mammalian species, including antigen-presenting cells in vivo (83), (iii) genetic 
stability, and (iv) strong adjuvant effects, very long-lived immune responses, and the capacity 
of inducing both humoral and cellular immune response and mucosal immunity (36). HSV-1 
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amplicons have also been used for the synthesis of proteins from other viruses, e.g. 
amplicon vector mediated synthesis of the full set of structural proteins allowed the assembly 
of hepatitis C VLP (48, 95, 96) and retrovirus VLPs (72, 87). In particular, the possibility of 
inducing local assembly of inert VLPs in the context of a quasi-infectious process holds great 
promises as new vaccine formulation.  
The goal of this study was to construct and evaluate HSV-1 amplicon vectors encoding 
individual or multiple structural RV proteins from a polycistronic transgene cassette in 
mammalian cells. Internal ribosome entry sites (IRES) in polycistronic vectors have been 
shown to support the expression of multiple genes from a single promoter (39, 66). As 
downstream cistrons are expressed at significantly lower levels (4, 18), the order of the RV 
genes was arranged within the polycistronic transgene cassette according to the relative 
abundance of the encoded protein in the virion. The expression of the RV genes was 
confirmed by Western blot and immune fluorescence analysis, and the generation of RVLPs 
in vector-infected cells was demonstrated by electron microscopy. Mice vaccinated with 
these vectors showed partial protection from challenge with wild type RV. These results 
demonstrate that polycistronic HSV-1 based amplicon vectors expressing genes for 
structural RV proteins are promising tools to study RV assembly in mammalian cells and may 
be useful as safe genetic vaccines against RV infections. 
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Material and Methods 
 
Cells and viruses 
African green monkey kidney epithelium, Vero (ATCC) and Vero 2-2 (90) cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 100 units/ml of penicillin G, 100 µg/ml of streptomycin, 0.25 µg/ml of 
amphotericin B, and, for VERO 2-2 cells, 500 µg/ml of G418 (Invitrogen, California, USA). 
The murine wild type (wt) RV strain EC was obtained from Dr. Harry Greenberg (Department 
of Medicine and Microbiology and Immunology, Stanford University School of Medicine, 
Stanford, California). The production and titration of wt RV EC used to challenge mice after 
vaccination was described previously (6). The simian RV strain SA11 was obtained from Dr. 
Catherine Eichwald (University of Zurich, Switzerland); it was propagated in MA104 cells and 
inactivated as previously described (21, 32). 
 
Construction of HSV-1 amplicon vectors 
All HSV-1 amplicon vectors used in this study encode enhanced green fluorescent protein 
(EGFP) to facilitate titration of the amplicon vector stocks and identification of vector-infected 
cells (15). In addition, the vectors express individual or multiple rotavirus genes and were 
constructed as follows: (i) pHSVD: The poliovirus IRES element was amplified with primers 
containing ClaI and XbaI restriction sites at the 5’ ends, respectively (for primer sequences, 
see Table 1), using plasmid pQuattro (kindly provided by M. Fussenegger, Institute of 
Biotechnology, Swiss Federal Institute of Technology, ETH Zurich, Switzerland) as template. 
The resulting PCR product (IRES2) was inserted between the ClaI and XbaI sites of pHSVS, 
which contains a transcription unit consisting of the HSV-1 immediate-early (IE) 4/5 
promoter, an IRES, and the SV40 polyadenylation signal (15) (ii) pHSVT: A third IRES 
sequence, derived from encephalomyocarditis virus (EMCV) was amplified with primers 
containing SpeI and Ecl136II restriction sites at the 5’ ends, respectively, using plasmid 
pQuattro as the template. The resulting PCR product was inserted between the SpeI and 
Ecl136II restriction sites of pHSVD. The resulting HSV-1 amplicon plasmid pHSVT contains 
three IRES signals between the HSV-1 IE 4/5 promoter and the SV40 polyadenylation signal. 
The HSV-1 amplicon vectors expressing the RV structural genes of strain RRV have been 
generated as follows (see also Table 1 and Fig 1A): (i) pHSVS[VP2]: The VP2 gene was 
amplified with primers containing SalI restriction sites at the 5’ ends using plasmid 
pVP2_RRV_Lopez (kindly provided by S. Lopez, Universidad Nacional Autonoma de Mexico 
(UNAM), Morelos, Mexico) as the template. The resulting PCR product was inserted into the 
SalI restriction site of pHSVS. (ii) pHSVS[VP6]: The VP6 gene was amplified with primers 
containing SalI restriction sites at the 5’ ends, using plasmid pENTR-VP6_RRV (M. Berois, 
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Universidad de la Republica, Montevideo, Uruguay) as the template. The resulting PCR 
product was inserted into the SalI restriction site of pHSVS. (iii) pHSVS[VP7]: The VP7 gene 
was amplified with primers containing AsuII restriction sites at the 5’ ends, using plasmid 
pVP7_RRV_Lopez (S. Lopez, Morelos, Mexico) as template. The resulting PCR product was 
inserted into the AsuII restriction site of pHSVS. (iv) pHSVD[VP6/2]: The VP6 PCR product 
described under (ii) was also subcloned into the SalI site of pHSVD resulting in pHSVD[VP6]. 
VP2 was amplified from plasmid pVP2_RRV_Lopez with primers containing AscI and ClaI 
restriction sites at the 5’ ends, respectively, and inserted between the AscI and ClaI sites of 
pHSVD[VP6]. (v) pHSVD[VP7/6]: The VP7 PCR product described under (iii) was inserted 
also into the AsuII site of pHSVD resulting in pHSVD[VP7]. VP6 was amplified from plasmid 
pENTR-VP6_RRV with primers containing AscI and ClaI restriction sites at the 5’ ends, 
respectively, and inserted between the AscI and ClaI sites of pHSVD[VP7]. (vi) 
pHSVT[VP7/6/2]: The VP7 PCR product described under (iii) was inserted also into the AsuII 
site of pHSVT resulting in pHSVT[VP7]. The VP6 PCR product described under (v) was also 
inserted between the AscI and ClaI sites of pHSVT[VP7] resulting in pHSVT[VP7/6]. VP2 was 
amplified from plasmid pVP2_RRV_Lopez with primers containing XhoI restriction sites at 
the 5’ ends, and inserted into the XhoI site of pHSVT[VP7/6].  
 
Production of HSV-1 amplicon vector stocks 
Helper virus-free HSV-1 amplicon vector stocks were prepared as previously described (24, 
79, 80). The HSV-1 genome was provided in trans by a bacterial artificial chromosome (BAC) 
containing the HSV-1 genome with deletions in the DNA cleavage/packaging signals and the 
essential ICP27 gene (fHSV∆pac∆ICP27). Briefly, Vero 2-2 cells were co-transfected with 
amplicon plasmid DNA, the fHSV∆pac∆ICP27 BAC DNA, and plasmid pEBHICP27 (which 
provides the HSV-1 ICP27 gene in trans), using Lipofectamine and Plus Reagent (Invitrogen, 
California, USA). After 72 h, cells were scraped into the medium, sonicated, and the cell 
debris was removed by centrifugation. For titration, Vero 2-2 cells were infected with the 
amplicon vectors and, after 24 h, green fluorescent cells were counted using an inverted 
fluorescence microscope (Axio Observer inverted microscope, Zeiss AG, Germany). The 
titers were determined as transducing units (TU)/ ml and ranged between 2-8 x106 TU/ml.  
 
Western analysis of vector encoded RV structural proteins  
Cells were seeded at a concentration of 1x105 cells/well in 24-well tissue culture plates, and 
amplicon vectors were added at a multiplicity of infection (MOI) of 0.5 or 1 TU per cell. Total 
cell lysates were harvested at different time points after infection and separated on 10% SDS-
polyacrylamide gels. The fractionated proteins were transferred to nitrocellulose membranes, 
probed with the primary antibodies, and stained using anti-mouse (Sigma, Missouri, USA) or 
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anti-rabbit (Southern Biotech, Birmingham, USA) IgG antibodies conjugated with horseradish 
peroxidase (HRP), followed by detection with Amersham ECL Western Blotting Analysis 
System (GE Healthcare, UK) according to the manufacturer's instructions. Rabbit anti-
rotavirus polyclonal serum raised against whole virus (strain RF, provided by D. Poncet, 
CNRS/INRA, Gif-sur-Yvette, France), mouse anti-GFP monoclonal antibody (Jl-8, Santa 
Cruz, California, USA) and mouse anti-actin monoclonal antibody (Sigma, Missouri, USA) 
were used as primary antibodies. For stripping, membranes were incubated for 15 min with 
Stripping Buffer (Thermo Scientific, Rockford USA) and washed 3 times with PBS.  
 
Immunofluorescence assays  
Vero 2-2 cells were grown on 12 mm coverslips (0.17 mm thick) in 24-well plates and either 
mock infected or infected with amplicon vectors at a MOI of 0.5 TU per cell. The cells were 
fixed with 3.7% formaldehyde in PBS and treated with 0.1 M glycine in PBS. After 
permeabilization with PBS containing 0.2% Triton X-100 (PBS-T), the cells were blocked with 
PBS supplemented with 3% bovine serum albumin (PBS-BSA). Cells were incubated with 
rabbit anti-rotavirus serum (strain RF, provided by D. Poncet, Gif-sur-Yvette, France) diluted 
in PBS-BSA (1:400) for 90 min at RT and then washed three times with PBS. As secondary 
antibodies, goat anti-rabbit IgG(H+L)-Alexa Fluor 594 or 633 (Molecular Probes, Invitrogen, 
USA) were used at a dilution of 1:400. Cells were incubated with DAPI (1 µg/ml in PBS, 
Roche, Switzerland) to visualize nuclei. The ER was stained using lectin ConcanavalinA 
(ConA) conjugated with Alexa Fluor 594 (20µg/µl in PBS; Molecular Probes, Invitrogen, 
USA). After washing the cells with PBS and H2O, the coverslips were mounted in Glycergel 
(Dako Cytomation, Denmark) containing 25 mg/ml DABCO (Fluka, USA) to retard 
discoloration. Samples were analyzed using a confocal laser-scanning microscope SP2 
(Leica Microsystems, Wetzlar, Germany, 63x oil objective). 
 
Electron microscopy 
Cells were seeded at a density of 1.2x106 cells/plate into 6 cm2 tissue culture plates. The 
following day, cells were mock infected or infected with HSV-1 amplicon vectors at a MOI of 
0.5 or 1 TU per cell. After 48 h, the cells were scraped into the medium and cell membranes 
were disrupted by repeated cycles of thawing/freezing. The cell debris was removed by 
centrifugation and filtration through a 0.45 µm filter. The cleared supernatant was loaded 
onto a 10% sucrose cushion and concentrated at 100,000 g for 2h at 20°C. For protection, 
protease inhibitor (Protease inhibitor cocktail tablets complete, Mini, EDTA-free, 1 tablet per 
10 ml, Roche Diagnostics, Mannheim, Germany) was added to the supernatant. For immune 
electron microscopy, samples were adsorbed to carbon coated parlodion films mounted on 
300 mesh/inch copper grids (EMS, Fort Washington, PA, USA) for 10 min, blocked with PBS 
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containing 0.1% BSA (PBS-BSA/0.1%) for 10 min, incubated with the polyclonal anti-
rotavirus serum at a dilution of 1:1000 PBS-BSA/0.1% for 1 hour, washed several times with 
PBS-BSA/0.1%, incubated with goat anti rabbit IgG coupled to 12 nm colloidal gold particles 
(Jackson ImmunoResearch, West Grove, PA, USA), washed several times with PBS and 
H20, and stained with 2% phosphotungstic acid, pH 7.0 (Aldrich, Steinheim, Germany) for 1 
min. Specimens were analyzed in a transmission electron microscope (CM12, Philips, 
Eindhoven, The Netherlands) equipped with a CCD camera (Ultrascan 1000, Gatan, 
Pleasanton, CA, USA) at an acceleration voltage of 100 kV. 
 
RNA isolation and reverse transcription PCR 
Cells were seeded at a density of 5x105 cells per well in a six-well plate and, one day later, 
mock infected or infected with HSV-1 amplicon vectors at an MOI of 1. Total RNA from 
infected cells was harvested 24 h later using the total RNA purification kit NucleoSpin RNA II 
(Macherey-Nagel, Germany) according to the instructions provided by the manufacturer. An 
additional DNase digest was performed by adding 1 µl of DNaseI (Roche, Switzerland) per 
50 µl of RNA. The samples were incubated for 15 min at 37°C, inactivated for 10 min at 
75°C, and stored at –20°C. Reverse transcription of  total RNA was performed using the 
Reverse Transcription System (Promega) with random primers provided in the kit. As control, 
the reaction was performed without the enzyme. Per reaction, 1 µg of total RNA was used 
and incubated for 10 min at RT and for 30 min at 42°C; then the enzyme was inactivated for 
5 min at 95°C. The cDNA was used immediately for PC R or stored at –20°C. PCR of the 
cDNA was performed using the REDTaq ReadyMix PCR Reaction Mix (Sigma, Missouri, 
USA) and the primers shown in Table 1.  
 
Immunization of mice and sample collection  
Five weeks old BALB/c mice were previously confirmed to be negative for anti-rotavirus 
antibodies by ELISA. Mice were intramuscularly (i.m.) inoculated at days 0 and 21 with: (i) 5 
x 105 TU or 1 x 106 TU of HSVT[VP7/6/2], (ii) 5 x 105 TU or 1 x 106 TU of HSV[EGFP] or (iii) 
PBS buffer. Individual serum and fecal samples were collected from all mice at 0, 7, 20, 35, 
and 41 days after the first immunization. All animal procedures were conducted in 
accordance with the regulations of the Quilmes University Ethic Committee.  
 
Detection of antibody responses by ELISA 
For detection of RV specific Igs by ELISA, stool samples (10% in TNC buffer, 10 mM Tris, 
140 mM NaCl, 5 mM CaCl2, supplemented with 0.05% Tween 20 and Protease Inhibitor 
Cocktail; Sigma, Saint Louis, MO) and serum samples were diluted in PBS containing 1% 
casein and 0.2% Tween 20. Fecal suspensions were diluted 1/5 for IgG or IgA detection, and 
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serum samples were diluted 1/100 and 1/20 for IgG or IgA detection, respectively. To detect 
rotavirus specific IgG antibodies, 96-well plates were coated over night at 4°C with 
concentrated RV strain RRV in carbonate buffer. Diluted samples were added, and plates 
were incubated for 1 h at 37°C. HRP-conjugated goat  anti-mouse IgG (Fc) antibodies (Pierce 
Biotechnology, Rockford, IL) were added to the plates for 1 h at 37°C. Between steps, plates 
were washed three times with 0.2% Tween 20 in PBS. The o-phenylenediamine peroxidase 
substrate was then used for detection. The reaction was stopped after 15 min with sulfuric 
acid and the optical density at 490 nm was determined. To detect rotavirus specific IgA 
antibodies, 96-well plates were coated for 1 h at RT with goat anti-mouse IgA, α chain 
specific unconjugated antibodies in carbonate buffer. Diluted samples were added, and 
plates were incubated for 1 h at 37°C. Concentrated  rotavirus strain RRV was added and 
plates were incubated over night at 4°C. After wash ing, biotinylated goat anti-rotavirus 
polyclonal IgG was added, and plates were incubated for 1 h at 37°C. HRP-conjugated 
Streptavidin (United States Biological, Swampscott, MA) was added, and plates were 
incubated for 30 min at 37°C. Between steps, plates  were washed three times with 0.2% 
Tween 20 in PBS. Detection was performed as described above. 
 
Analysis of antibody responses 
Purified and concentrated RV strain RRV proteins were separated by SDS-PAGE (10%) and 
transferred to nitrocellulose membranes. After blocking with PBS containing 1% casein, the 
membranes were incubated with 1/50 dilutions of serum samples obtained at day 42 after 
immunization. Mouse hyperimmune serum against RV strain RRV was used as positive 
control. After washing, membranes were incubated with HRP-conjugated goat anti-mouse 
IgG (Pierce Biotechnology, Rockford, IL) followed by detection with a chemiluminescent 
substrate (PBL, Bernal, Argentina) according to the manufacturer's instructions. 
 
Virus challenge and detection of virus shedding 
Three weeks after the second immunization, mice were orally challenged with 104 shedding 
doses (SD50) of wt RV strain EC (6). To measure rotavirus shedding, stool pellets were 
collected from each mouse every day for 8 days after challenge and stored at -80°C. The 
collected samples were thawed and 10% dilutions were made in TNC buffer containing 
0,05% Tween 20 and protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO), and mixed 
well before debris was removed by centrifugation (2500 g, 10 min). The presence of rotavirus 
antigen in fecal samples was determined by ELISA as described previously (1). 
Measurement of protective efficacy of amplicon vectors was based on both the duration and 
amplitude of virus antigen shedding. Therefore, virus antigen shedding curves (OD versus 
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days post-challenge) of each animal were plotted and the area under the shedding curve for 
each animal was calculated and compared to that of the control group (33). 
 
Statistical analysis 
Statistical analysis was performed using the program GraphPad Prism (CA, USA). 
Comparison of the viral shedding and differences between animal groups were compared by 
Student’s t-test. P-Values were considered to be significant if less than 0.05 (p<0.05). 
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Results 
 
Polycistronic HSV-1 amplicon vectors encode structural RV proteins  
The HSV-1 amplicon vectors constructed for this study are shown in Fig. 1A. The order of the 
individual RV genes in the polycistronic vectors was based on the composition of the mature 
RV particle: the major constituent of the outer layer is glycoprotein VP7, of which 780 copies 
are grouped as 260 trimers; the intermediate layer is formed by 780 copies of VP6 arranged 
as 260 trimers; the innermost layer is composed of 120 copies of VP2. We hypothesized 
therefore that an equimolar ratio of the structural proteins is not strictly required and placed 
the VP2 gene, which encodes the least abundant structural protein after the second or third 
IRES. Vector-mediated expression of RV genes VP2, VP6 and VP7 was confirmed by 
Western analysis of total cell lysates harvested at 24 h after infection (Fig. 1B). As expected, 
in pHSVD and pHSVT-infected cells, expression of downstream cistrons was markedly 
reduced. Accordingly, the intensity of the EGFP band also decreased with increasing position 
number in the polycistron (Fig. 1B, lower panel).  
Next, we examined the synthesis and subcellular localization of the structural RV proteins in 
HSV-1 amplicon vector-infected cells by indirect immunofluorescence using a polyclonal 
rabbit anti-RV serum (Fig. 2). EGFP fluorescence was used to identify vector-infected cells. 
VP2 and VP7 were observed as small foci with some aggregation around the nucleus (Fig. 
2A). As previously described (20, 54), the major capsid protein VP6 formed fiber-like 
structures in the cytoplasm (Fig. 2A). In cells infected with pHSVD[VP6/2], pHSVD[VP7/6], or 
pHSVT[VP7/6/2], the RV proteins were distributed in a punctuate pattern throughout the 
cytoplasm and no fiber-like structures were detected (Fig. 2B). As previously observed by 
Western blot (Fig. 1B), the intensity of EGFP fluorescence decreased with increasing 
position number in the polycistron (Fig. 2, A and B). In wt RV infected cells, the outer capsid 
glycoprotein VP7 is a membrane protein located at the endoplasmic reticulum (ER) (20, 59). 
To determine if VP7 localizes to the ER also when encoded by HSV-1 amplicon vectors, cells 
were infected with pHSVS[VP7] and, 24 h later, stained with ConA (Fig. 2C) and a polyclonal 
rabbit anti-RV serum. Confocal laser scanning microscopy revealed that VP7 expressed from 
HSV-1 amplicon vectors indeed was located at the ER as it co-localized with ConA staining.  
Taken together, these results demonstrate that the three RV structural genes VP2, VP6, and 
VP7 are expressed from the different polycistronic vectors, however with reduced levels 
when placed after IRES. The subcellular localization of the three vector encoded proteins 
was comparable to that described for wt RV encoded VP2, VP6, and VP7 proteins (11, 58). 
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HSV-1 amplicon vectors mediate the generation of rotavirus-like particles (RVLPs) in vector-
infected cells  
In order to examine the potential assembly of the vector encoded structural proteins into 
RVLPs, cells were infected with pHSVD[VP6/2] and pHSVT[VP6/2/7] amplicons. After 48 h, 
cell lysates were prepared for immunogold staining and electron microscopy (Fig. 3). 
Purified, inactivated wt RV strain SA11 served as positive control, mock-infected cells as 
negative control (not shown). Infection of cells with pHSVD[VP6/2] resulted in the generation 
of double-layered particles (Fig. 3A), while infection with pHSVT[VP6/2/7] resulted in the 
formation of triple-layered RVLPs (Fig. 3B). Lysates from the pHSVT[VP6/2/7]  infected cells 
were also examined by negative staining in absence of immunogold labeling in order to 
obtain a higher structural resolution. Triple-layered RVLPs were clearly visible (Fig. 3C). 
Western analysis of the concentrated samples used for electron microscopy confirmed that 
the observed RVLPs consisted of the RV structural proteins (not shown). The polyclonal 
antiserum used for immunogold detection efficiently labeled partially disrupted wt RV SA11 
particles but not full particles (Fig. 3D). This may be due to the high anti-VP6 activity of the 
polyclonal antiserum, which can efficiently label the exposed protein in disrupted particles, 
but not that of complete particles. This could, in part, be due to the serotype specific nature 
of the exposed epitopes of VP7, which react very poorly with the heterotypic anti-RF 
antiserum. Taken together, these data demonstrate that the HSV-1 amplicon vectored 
delivery of structural RV genes supports the assembly of RVLPs in mammalian cells. 
 
Splicing of rotavirus genes expressed from HSV-1 amplicon vectors 
As HSV-1 derived vectors deliver transgenes into the host cell nucleus while RV replicates in 
the cytoplasm, and because several splicing donor and acceptor sites are predicted on the 
VP6 sequence (Fig. 4A; (91), we examined the VP6 RNA from vector-infected cells for 
possible splicing events.  For this, total RNA was extracted from vector infected or mock 
infected cells at 24 hpi and reverse transcribed. Subsequent PCR was performed to amplify 
the complete open reading frame (ORF) of VP6 with a size of approximately 1214 bp (see 
Fig. 4A). RT-PCR of GAPDH in presence or absence of reverse transcriptase served as 
control (Fig. 4B, right panel). Interestingly, RT-PCR of cDNA from pHSVS[VP6], 
pHSVD[VP6/2] or pHSVT[VP7/6/2]  infected cells revealed a prominent band of approximately 
400 bp in addition to the full-length band (Fig. 4B, left panel). Sequence analysis of the 400 
bp band revealed a truncated VP6 gene, in which the middle part of VP6 was deleted, as 
predicted from the splice donor and acceptor sites. The start and stop codons of the VP6 
ORF were still in frame and could potentially give rise to a truncated protein with a calculated 
molecular weight of approximately 14 kDa. Besides VP6, there are splicing sites predicted 
also for VP2, but no splicing was detected for either VP2 or VP7 (not shown).  
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The Vero 2-2 cells used for the experiments described above express the HSV-1 ICP27 
gene. ICP27 is an essential immediate early protein, which, besides other functions, can 
inhibit splicing of both viral and cellular RNA (35, 93). To find out if HSV-1 amplicon vector-
mediated production of rotavirus proteins and RVLPs is possible only in cells in which 
splicing is inhibited, we next analyzed protein synthesis and RVLP production in vector 
infected, parental Vero cells. No differences concerning RV protein synthesis (Fig. 4C) or 
RVLP structure (Fig. 4D) were observed between Vero and Vero 2-2 cells infected with 
HSVS[VP6] (Fig. 4C) or pHSVD[VP6/2] (Fig. 4D). The intensity of the band corresponding to 
full length VP6 protein was comparable between Vero and Vero 2-2 cells, indicating that 
even if splicing of VP6 RNA occurred, there was no major decrease in the production of the 
full length protein. Moreover, the use of splicing inhibitors did not result in increased 
accumulation of vector encoded VP6 protein (not shown). 
 
Immunization of mice with pHSVT[VP7/6/2] resulted in partial protection from virus challenge 
After demonstrating the assembly of the vector-encoded RV proteins into RVLPs, the 
potential usefulness of these HSV-1 amplicon vectors for vaccination against RV infection 
was evaluated by assessing their ability to induce specific antibody responses in vector-
vaccinated mice. For this, Balb/c mice were inoculated i.m. with HSVT[VP7/6/2] or, as 
control, with the empty vector pHSV[EGFP] or PBS in a prime-boost regimen using a dose of 
5 x 105 or 1 x 106 TU per inoculation (Fig 5A). RV-specific antibodies in serum and feces 
collected from mice at days 0, 7, 20, 35, and 41 after the first immunization were determined 
by ELISA and Western analysis as described in Material and Methods. Significant 
differences in the average level of serum or fecal IgG and IgA antibody levels between mice 
immunized with HSVT[VP7/6/2] and the control mice immunized with pHSV[EGFP] could not 
be observed by ELISAs (data not shown). However, after the second immunization VP6 
specific antibodies were detected in all serum samples by Western analysis (Fig. 5B). VP2 
specific antibodies were observed only in three out of seven sera (Fig. 5B, lanes 3, 4, 7), 
while VP7 specific antibodies were not detected in any of the samples analyzed. Series of 
experiments performed with doses of either 5 x 105 (Fig. 5B, lanes 1-4) or 1 x 106 TU (Fig. 
5B, lanes 5-7) per inoculation yielded similar results. RV-specific fecal or serum IgA 
antibodies and fecal IgG antibodies of mice immunized with HSVT[VP7/6/2] were below the 
sensitivity of the ELISA.  
Next, we addressed the question whether vector immunized mice are protected from oral 
challenge with wt RV. In the adult mouse model, infection with RV does not induce disease 
and protection is therefore defined as the absence of detectable fecal viral antigen following 
challenge, and partial protection is defined as reduced quantities of fecal viral antigen 
compared to that shed by PBS-inoculated mice after challenge (10, 100). Accordingly, 
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protection from RV infection upon challenge was evaluated by comparing antigen shedding 
in mice vaccinated i.m. with two doses of pHSVT[VP7/6/2] or pHSV[EGFP] to mock 
vaccinated mice (PBS). Animals were orally challenged three weeks after the second 
immunization with live RV strain EC (104 SD50). Fecal samples were collected from day 0 to 8 
post challenge, and antigen levels were monitored by ELISA (Fig. 5C). Protection against 
infection was determined as total viral shedding in feces by calculating the area under the 
curve (AUC). The percent reduction in shedding was determined by comparing the AUC of 
the vaccinated mice to the mean AUC of the PBS control group. Mice immunized with two 
doses of 1 x 106 TU of pHSVT[VP7/6/2] were partially protected from RV infection. They 
demonstrated a significant decrease (p<0.05) in the shedding of RV (39.9% reduction) in 
feces after oral challenge with wt RV EC compared to control mice (Fig. 5C). Mice 
immunized with 5 x 105 TU of pHSVT[VP7/6/2] had a non-significant level of reduction of RV 
antigen shedding in feces (18.7%, p>0.05). Taken together, immunization of mice with 
pHSVT[VP7/6/2] resulted in a dose dependent partial protection of vaccinated mice as 
defined for the adult mouse model. However, only a low antibody response was detectable, 
which suggests that this protection did not correlate with the variable antibody response 
observed.  
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Discussion 
 
The use of VLPs as vaccines is very promising because of their safety compared to live 
attenuated virus vaccines. Despite the lack of any genetic material, VLPs retain the high 
immunogenicity of the parental viral particle. VLPs could serve also as carriers of foreign 
epitopes from bacterial or viral pathogens or drugs, which could enhance the immune 
response to the applied vaccine. Moreover, VLPs containing structural proteins from different 
serotypes could be combined. The use of a mammalian delivery system, such as HSV-1 
amplicon vectors to launch the in situ production of heterologous VLPs, provides the 
advantage that time consuming and expensive purification of VLPs is not required. Indeed, 
here we demonstrated that HSV-1 amplicon vectors can mediate the efficient in situ 
production of RV structural proteins and RVLPs in vector-infected cells, despite the facts that 
(i) the normal site for RV replication locates in so-called viroplasms the cytoplasm while HSV-
1 amplicon vectors deliver the RV genes into the nucleus, (ii) and several splicing sites are 
predicted in the ORF of VP6 and VP2 (91). However, our results show that splicing of VP6 
RNA did not prevent the production of the full-length protein and the use of splicing inhibitors 
did not result in increased production of vector-encoded VP6 protein or RVLPs. When used 
as vaccine vectors in the adult mouse model (100), a RV VP6 specific antibody response 
was detected in the sera of all immunized animals. Although RV-specific fecal or serum IgA 
antibodies or fecal IgG antibodies were below the detection limit, significant partial protection 
from challenge with wt RV was observed in the immunized mice. The molecular mechanisms 
regulating protection against RV are still unclear and the immunological mediators remain to 
be established. In the mouse model, different immune effectors appear to be responsible for 
protection depending on whether immunity is elicited by natural infection, vaccination with 
attenuated strains, or immunization with non-living vaccines (3). Also the protective 
mechanisms are different depending on the inoculation route, adjuvant and even on the 
source and level of purification of the preparation (46, 75). Both in humans and animal 
models, protection after natural infection or oral vaccination with live attenuated RV 
moderately correlates with specific serum and fecal immunoglobulins, particularly intestinal 
dimeric IgA (25, 45), indicating that neutralizing antibodies can play a role in protection. 
However, in some animal models, and particularly through the extensive use of the adult 
mouse model to address mechanistic questions, alternative ways of protection were clearly 
demonstrated (12, 23, 104). While protection induced by subunit vaccines is dependent 
exclusively on CD4+ T cells (64), the same does not apply when attenuated RV is used for 
vaccination. In this case, the protection does not solely rely on IgA (70) or T cells (26). 
Infection with wild-type HSV-1 results in a potent host immune response involving both, the 
innate and the adaptive immune system (49), but the virus is also able to evade host 
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immunity through a variety of mechanisms based on immuno-modulatory gene products 
such as the virion host shut-off protein (81) or the ICP47 protein (106). Although HSV-1 
amplicon vectors do not express any viral genes, including immuno-evasive genes, they are 
composed of some 40 different virus-encoded structural proteins, which are delivered into 
the cell during infection. This could lead to intrinsic cellular responses, triggering tissue alarm 
signals and innate responses like cytokine secretion, and promoting a bias to a TH1-like 
adaptive immune response. Hence, as HSV-1 amplicon vectors trigger per se a TH1 
response, further adjuvants are not necessary. 
Due to the high prevalence of HSV-1 in humans, one major concern about the use of HSV-1 
derived vectors as vaccines is the possible impact of pre-existing antiviral immunity, which 
may lead to vector neutralization or rapid clearance of vector-transduced cells. This issue 
was addressed in one study where mice were immunized with a heterologous HSV-1 strain 
to generate an anti-HSV-1 immune response and then subsequently inoculated with helper 
virus-free HSV-1 amplicons vectors. Although significant titers of neutralizing antibodies were 
present in those mice, HSV-1 amplicon vector mediated cellular immune responses were 
only modestly reduced (36), indicating that pre-existing immunity may not prevent the 
successful use of HSV-1 amplicon vector-based vaccines.  
HSV-1 amplicon vectors have been used to express HIV envelope glycoprotein gp120 (36). 
A single dose of 1 x 106 transducing units of gp120 expressing HSV-1 amplicon vectors 
resulted in strong antigen-specific and long-lasting cellular and humoral responses in mice. 
Subsequent work showed that amplicon vector-induced immune responses could be strongly 
enhanced by prior priming with either a DNA vaccine encoding the same antigen or by initial 
priming with the amplicon vectors (99). Taken together, amplicon vectors have shown 
promising results as vaccine delivery system in several preclinical studies, including animal 
models for cancer treatment (56, 78, 86, 94) and prophylactic immunizations against 
infectious pathogens (31, 36, 53, 84). HSV-1 amplicon vectors have also been used to 
express the foot and mouth disease virus (FMDV) structural genes resulting in the assembly 
of FMDV empty particles. Mice vaccinated in a prime/boost regimen with 5 x 105 transducing 
units of this amplicon vector elicited a FMDV-specific humoral response in the absence of 
adjuvants and were partially protected against challenge with a high dose of live FMDV (15). 
The present work suggests that HSV-1 amplicon vectors are able to elicit antigen-specific 
immune responses to the RV proteins and, at least, partial protection against challenge with 
wt RV. Perhaps these responses could be further enhanced by evaluating different routes of 
vaccination. HSV-1 amplicon vectors have many properties that make them promising 
vaccine vectors. Their large transgene capacity (up to 152 kbp) allows the simultaneous 
encapsidation of multiple copies of a transgene/antigen or the expression of multiple different 
transgenes/antigens, as shown in this work. In particular, amplicon vectors are safe because 
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they can be produced in the absence of helper virus and, therefore, do not express any HSV-
1 genes (24, 71, 79, 80). The production of helper virus-free amplicon vector stocks is based 
on co-transfection of amplicon plasmids with HSV-1 helper genomes and is therefore limited 
as the vectors cannot be further amplified. Further optimization and refinement of the 
currently used helper virus-free systems, like a more efficient delivery of the BAC helper 
genome into mammalian cells, will be required to achieve titers high enough for clinical 
testing. At present, no method combining a total absence of contaminating helper particles 
with ability to produce very large amounts of amplicon particles is available. However, other 
packaging systems have been developed which allow the production of safe and high titered 
amplicon vector stocks that contain 0.05 to 1.0 % of defective, non-pathogenic helper viruses 
(14, 57, 107). In addition to improvements to vector production, the amplicon vector itself 
could be further optimized for use as a vaccine vector. For example, immuno-modulating 
genes like the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) could 
be included in the vectors to co-stimulate the immune cells and to enhance the humoral and 
cellular immune response (19, 92, 103). For RNA virus genes, sequences should be adapted 
for the expression in mammalian cells; cryptic introns modified and splice donor/acceptor 
sites mutated. The polycistronic amplicon vector used here resulted in a reduced level of 
expressed transgene from the downstream cistrons (Fig. 1B, 2). The use of individual 
promoters for the different transgenes or the replacement of one or two IRES by the viral 
cleavage factor 2A of FMDV, a feature widely used in bicistronic vectors (8, 40), could be 
another strategy to enhance transgene expression and amount of RVLPs produced. 
In conclusion, the presented work suggests that HSV-1 amplicon vectors are able to elicit 
antigen-specific immune responses to the RV proteins and partial protection against 
challenge with wt RV, opening the possibility of using the described vectors in prophylactic 
vaccinations against RV infections. 
.
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FIGURE LEGENDS 
 
Figure 1. RV genes expressed from HSV-1 amplicon vectors.  
A) Schematic representation of the HSV-1 amplicon vectors expressing or co-expressing RV 
genes VP2, VP6 and VP7. Polycistronic expression is facilitated by two picornavirus IRES 
and an encephalomyocarditis virus (EMCV) derived IRES (28), and controlled by the HSV-1 
IE4/5 promoter. All vectors contain the EGFP reporter gene to support titration of vector 
stocks. The HSV-1 origin of DNA replication (oriS) and packaging/cleavage signal (pac) as 
well as the restriction sites used for cloning are indicated. B) Vero 2-2 cells were infected 
with HSV-1 amplicon vectors (MOI 1), and total cell lysates were harvested at 24 hpi. 
Transgene expression was analyzed by Western blot using a polyclonal rabbit anti-RV serum 
for detection of RV proteins or a monoclonal anti-GFP antibody to stain EGFP. Detection of 
actin was used as loading control. Purified and inactivated wt RV strain SA11 served as 
positive control.  
 
Figure 2. Intracellular distribution of HSV-1 amplicon vector encoded RV proteins.  
Vero 2-2 cells were infected with HSV-1 amplicon vectors (MOI 0.5). The cells were fixed 24 
hpi, permeabilized and stained with a polyclonal anti-RV serum (anti-RV) and an Alexa 
Fluor594 conjugated secondary antibody (red) and analyzed using an inverse confocal laser-
scanning microscope. EGFP fluorescence served to identify vector-infected cells (green); 
nuclei were stained with DAPI (blue). Scale bars = 5 µm. A) Cells infected with HSVS 
encoding VP2, VP6 or VP7. B) Cells infected with HSVD and HSVT encoding different 
combinations of VP2, VP6 and VP7. C) HSV-1 amplicon vector encoded VP7 is localized at 
the ER, as determined by staining with Alexa Fluor594-conjugated lectin ConA (purple).  
 
Figure 3. Electronmicrographs of HSV-1 amplicon vector encoded RVLPs.  
Vero 2-2 cells were infected with HSV-1 amplicon vectors (MOI 1). Two days post infection, 
RVLPs were purified over a sucrose cushion and the concentrated particles were analyzed 
by electron microscopy. (A, B, D) Immunogold staining using a polyclonal anti-RV serum and 
a secondary antibody coupled to 12 nm gold particles. (A) Double-layered RVLPs from cells 
infected with HSVD[VP6/2]. (B) RVLPs from cells infected with HSVT[VP7/6/2]. (C) Negative 
staining of RVLPs from cells infected with HSVT[VP76/2]. (D) Purified inactivated wt RV 
strain SA11. Scale bars = 50 nm. 
 
Figure 4. The HSV-1 amplicon vector encoded VP6 RNA is spliced. 
A) Schematic representation of the predicted splicing donor and acceptor sites on the VP6 
RNA. Primers used for detection of the VP6 ORF are indicated as VP6 fwd and VP6 rev 
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(Table 1). The amplified full length VP6 ORF (1214 nt) and the truncated form of VP6 (387 
nt) are shown. B) Reverse transcription PCR of total RNA isolated from infected cells (see 
Table 1 for primer sequences). Left panel: Amplification of VP6 sequences using the primers 
VP6 fwd and VP6 rev. The detected bands correspond to the sizes predicted for full length 
and truncated VP6 sequences. Right panel: Amplification of GAPDH sequences was used as 
control. Reactions were performed in presence (+) or absence (-) of reverse transcriptase. 
Negative control: mock-infected cells. C) Immunoblot of HSVS[VP6] infected Vero and Vero 
2-2 cells. The polyclonal anti-RV serum was used for detection of RV proteins, a monoclonal 
anti-GFP antibody to stain EGFP, and actin staining as loading control. Purified and 
inactivated wt RV strain SA11 served as positive control. D) Electronmicrograph (negative 
staining) of double-layered RVLPs produced in Vero cells infected with HSVD[VP6/2]. RVLPs 
purified from total cell lysates were concentrated over a sucrose cushion. Scale bar = 100 
nm. 
 
Figure 5. Immunization of mice with HSVT[VP7/6/2] confers partial protection from 
challenge with wt RV. 
A) Timetable indicating the immunization schedule. Mice (four to six mice per group) were 
immunized (i.m.) at day 0 and boosted at day 21 with 5 x 105 TU or 1 x 106 TU of 
HSVT[VP7/6/2] or HSV[EGFP]. A third group of mice received PBS injections at days 0 and 
21. Stool and serum samples were collected at days 0, 7, 21, 35 and 42 after the first 
immunization. Three weeks after the second immunization, mice were orally challenged with 
104 SD50 of wt RV strain EC, and stool samples were collected every day for eight days post 
challenge. B) Western analysis of RV specific antibodies in sera of immunized mice. RV 
(strain RRV) proteins were separated by SDS-PAGE and blotted onto nitrocellulose 
membranes. Membranes individually probed with sera diluted 1/100 from mice immunized 
with 5 x 105 TU (lanes 1 to 4) or 1 x 106 TU (lanes 5 to 7) of HSVT[VP7/6/2] or HSV[EGFP] 
(lanes 8 and 9) are shown. Mouse hyperimmune serum against RV strain RRV was used as 
positive control to identify VP2, VP6 and VP7. The results shown represent one of two 
independent experiments. C) Mice immunized with HSV-1 amplicon vectors were challenged 
as shown in A). The presence of RV antigen in stool was measured by ELISA and virus 
antigen shedding curves of each animal were plotted, and the area under the shedding curve 
(AUC) for each animal over 8 days was calculated and compared to that of the control group 
(PBS, 100 %). Mean AUC per group are shown. Error bars indicate the standard deviation of 
the mean AUC per group. Differences between groups were compared by Student’s t-test. 
Asterisk: statistically significant (p<0,05). 
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Table 1 Primer list 
Gene Primer fwd Primer rev Template Construct(s)
IRES2 gcctgatcaATCGATgtttaaactta aattTCTAGAtcgcactagtctcgagaatcca pQuattro31 pHSVD
CITE ctttACTAGTacaggtgtccactcccaggtcca ccatGAGCTCtgcaggaattatcccggggttgt pQuattro31 pHSVT
VP2 ttaaGTCGACatggcgtacagaaagcgtggag tagtGTCGACttacagttcgttcatgatgcg S.Lopez pHSVS[VP2]
VP2 aatGGCGCGCCatggcgtacagaaagcgtggag tatATCGATttacagttcgttcatgatgcg S.Lopez pHSVD[VP6/2]
VP2 ttaaCTCGAGatggcgtacagaaagcgtggag tagtCTCGAGttacagttcgttcatgatgcg S.Lopez pHSVT[VP7/6/2]
VP6 aggaGTCGACatggatgtcctatactctttg agctGTCGACtcatttaatgagcatgcttct pENTR-VP6_RRV2 pHSVS[VP6]pHSVD[VP6/2]
VP6 gcagGGCGCGCCatggatgtcctgtactccttg agctATCGATtcatttgacaagcatgcttct pENTR-VP6_RRV2 pHSVD[VP7/6]pHSVT[VP7/6/2]
VP7 ctctTTCGAAatggactttattatttacaga ggtgTTCGAActatattctataatagaatgca S.Lopez
pHSVS[VP7]
pHSVD[VP7/6]
pHSVT[VP7/6/2]
EGFP agccgctaccccgaccacat ttgctcagggcggactgggt cDNA RT-PCR
GAPDH ggggagccaaaagggtcatcatct acgcctgcttcaccaccttcttga cDNA RT-PCR
1 M. Fussenegger, ETHZ, Zurich, Switzerland
2 M. Berois, Montevideo, Uruguay
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2.2 Results Part II: Foot-and-Mouth disease virus 
2.2.1 Aim of the project 
FMDV is the type species of the genus Aphtovirus of the Picornaviridae family. The highly 
infectious disease caused by this virus continues to be of major economic importance across 
the world. The FMDV genome consists of a single copy of a positive-sense, single-stranded 
RNA, which encodes a single open reading frame. This open reading frame gives rise to a 
polyprotein, which is proteolytically processed by virus-encoded proteases. The 3C protease 
cleaves the capsid precursor protein to produce all the capsid proteins. FMDV has a small 
non-enveloped icosahedral capsid with a diameter of around 25 nm. The capsid is formed 
from 60 copies each of the four viral structural proteins VP1, VP2, VP3 and VP4. Natural 
FMDV empty particles have been shown to stimulate the same level of neutralizing 
antibodies as full particles. 
The aim of this project was to construct HSV-1 amplicon vectors, which co-express the 
FMDV structural proteins and the 2A and 3C proteases; and to evaluate the capability of the 
vectors to support the in situ production of FMDV-like particles (VLPs) in the vector-
transduced cells. The potential use of these vectors for the generation of genetic vaccines 
was assessed by vaccination of mice and evaluation of specific immune responses to the 
corresponding antigens. 
This project was designed and performed in collaboration with the laboratory of CEVAN-
CONICET, Buenos Aires, Argentina. 
 
2.2.2 Paper FMDV 
 
HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease 
virus antigens in mammalian cells can be used for genetic immunization 
 
Manuscript published in Vaccine 28 (2010) 
 
 
Own contribution to the manuscript 
Cloning of the HSV-1 amplicon vectors 
Characterization of the gene expression by immune fluorescence 
Production of vector stocks for immunization of mice 
Analysis of VLPs by electron microscopy (assistance from E. Schraner) 
Inoculation of mice for immune histochemistry 
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3 Perspectives 
 
The aim of this study was to evaluate the feasibility of HSV-1 based amplicon vectors as 
genetic vaccine candidates. Two RNA viruses, rotavirus and Foot-and-mouth disease virus 
(FMDV), both of which cause severe diseases, have been chosen for this work. At present, 
most of the currently licensed vaccines are based on live attenuated or inactivated viruses or 
subunits of the virus particle. Besides safety concerns and the need of high-risk facilities for 
the production of the vaccine strains, which makes the vaccines expensive, the viruses 
studied in this thesis consist of a RNA genome. RNA viruses are known to mutate fast in a 
relatively short time. This high antigenic variation and the already existing amount of 
circulating serotypes of the two viruses makes it even more important to generate a vaccine 
platform, which makes it possible to create in a relatively short time efficient and safe 
vaccines. 
In the present work, HSV-1 amplicon vectors have been designed to support the in situ 
production of virus-like particles (VLPs) in the vector-transduced cells. VLPs are very 
promising vaccine candidates, as they are structurally similar to the infectious virus, but they 
lack viral nucleic acid, are non-infectious and are therefore totally safe. Thus, they combine 
many of the advantages like the high antigenicity of the viral capsid (inactivated or attenuated 
whole-virus vaccines) with a high safety level (viral subunit vaccines). Besides these 
convincing advantages, there are major limiting factors concerning the use of VLPs as 
vaccines candidates, including the high production and purification costs to obtain the large 
amounts of highly purified and stable particles needed for large clinical trials. The chosen 
strategy to produce VLPs directly in the vector-infected cells or organism has the immense 
advantage that there is no need to purify the produced VLPs prior to injection. Moreover, 
when compared to injection of purified VLPs, delivering the genes into the cells results in the 
intracellularly production of the antigen, and the immune response generated mimics that 
induced by replication of live pathogen, which could lead to development of both humoral 
and cellular responses. This feature is also true for DNA vaccination, but using HSV-1 
amplicon vectors for the delivery of the antigen needs no addition of an adjuvant (1). The 
baculovirus system is well established and known to generate high levels of foreign proteins, 
but the posttranslational processing of proteins in insect cells greatly differs from that in 
mammalian cells. Using mammalian cells for vaccine vector production supports the 
appropriate modifications and authentic assembly of the VLPs, resulting in even better 
mimicking of the wild-type virus strain. 
On the other hand, a critical point of using HSV-1 amplicon vectors for the generation of 
vaccines against RNA virus infections is the fact that HSV-1 replicates in the nucleus, 
whereas both studied RNA viruses do not enter the nucleus of the infected cells. This 
Andrea Laimbacher PhD Thesis Perspectives 
 76 
concern was addressed in the current work on rotavirus vectors and no impact on the protein 
level or number of VLPs produced could have been demonstrated, although aberrant splicing 
events have been identified. 
HSV-1 amplicon vectors are easy to construct, and their large transgene capacity allows the 
incorporation of several genes of interest, up to about 150 kb, and the encapsidation of 
several copies of the transgene cassette. The helper virus-free system used in this study 
allows the production of vector stocks that are free of contaminating HSV-1, providing a high 
safety level of these vectors. The limiting factor when using this BAC-based system is the 
relatively low amount of resulting vector stocks. In the case of FMDV, toghether with our 
collaborators in Argentina, we immunized cows with the amplicon vectors (not described in 
this thesis). The amount of vector used for the immunization was 1x107 TU per injection. The 
same prime and boost regimen was used as previously in mice. Upon challenge, none of the 
three vaccinated cows was protected and, none of the cows produced virus-specific 
antibodies. From this preliminary experiment we concluded that the amount of injected 
antigen was simply not enough to elicit a detectable antibody response, as researchers using 
replication-deficient adenoviral vectors used doses of 5x109 pfu per animal (summarized in 
(5)). Therefore, the need of a more efficient packaging system, which still produces helper-
free stocks, but which yields in higher amounts of vectors is of great importance for future 
possible application in larger trials and in other animals than mice. 
The transgene cassettes used in this work were shown to efficiently express the viral genes 
of interest, leading to the in situ generation of VLPs in the vector-infected cells. Therefore it 
could be an alternative to use another virus platform, but the same strategy of generating 
VLPs in the vector-infected organism, specifically to use the transgene cassettes 
characterized in this study. Such a candidate virus could be the Orf virus (ORFV), which 
belongs to the Genus Parapoxvirus of the family Poxviridae. Orf virus based vectors, which 
express foreign antigens, have been shown to be immunogenic and provide protection 
against several viruses in a number of animal models. This includes a study performed in 
mice with pseudorabies virus (4), in rats with borna disease virus (7) and in pigs with 
classical swine fever virus (12) and pseudorabies virus (2). 
FMD is a highly contagious viral vesicular disease of cloven-hoofed animals that generally 
causes severe economic losses. FMDV affects mostly cattle, pigs and sheep, but it can infect 
and cause disease to more than 70 domestic and wild animal species (6). The high 
economic impact of FMD is based on virological characteristics of the causing virus, like high 
speed of replication, short incubation time, high contagiousness because of high level of 
virus excretion via aerosols and a high mutation rate resulting in constant antigenic changes. 
If the virus is not controlled quickly and efficiently, it spreads extremely rapidly in a 
susceptible population (11). 
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Seven distinct FMDV serotypes have been described so far. Immune responses induced by 
FMDV infection or vaccination with one serotype do not cross-protect against other 
serotypes, and in many cases, protection may be restricted only to closely related strains 
within the same serotype. The current available vaccines are based on chemically 
inactivated whole virus preparations used in conjunction with an adjuvant (5), which are very 
successful in reducing the number of disease outbreaks and the spread of the virus during 
an outbreak, but there are some concerns and limitations of this inactivated FMDV vaccine: 
(i) The need of expensive high-containment facilities required for the production of the 
vaccine, (ii) The difficulties to distinguish between vaccinated and infected or convalescent 
animals with currently approved diagnostic tests, as the vaccine contains contaminating viral 
non-structural proteins, (iii) The vaccine does not induce rapid protection against challenge 
by direct or indirect contact resulting in a 7 to 14 days window of susceptibility of the 
vaccinated animals and (iv) vaccinated animals can become long-term carriers following 
contact with FMDV (5, 9). There are three different states with regard to FMD according to 
The World Animal Health Organisation (OIE, office international des epizooties): (i) FMD 
present with or without vaccination, (ii) FMD free with vaccination and (iii) FMD free without 
vaccination. Only countries stated FMD free without vaccination possess full access to the 
international trade. For a country to be considered free of FMD and therefore to regain full 
access to livestock trade, it is crucial to distinguish between antibodies generated during a 
natural infection and from those produced after vaccination (6). FMD is monitored based on 
serological tests and both, natural infection and vaccination with conventional inactivated 
vaccines results in a seropositive animal, which is the reason why these vaccines are not 
routinely used, as the country would loose its disease-free status. Also, the vaccinated 
animals have to be slaughtered to re-establish the FMDV-free status (3). 
To overcome the above described concerns related to the existing vaccines, two major 
points need to be fullfilled for a new vaccine to be successful: providing rapid protection to 
limit virus spread and being able to distinguish vaccine-inoculated animals from infected 
animals. One widely studied approach is to use a replication-defective human adenovirus to 
deliver the parts of the genome required for empty capsid synthesis and assembly, the 
protein precursor P1-2A and the protease 3C (5, 8, 10), the same region also used for this 
study. 
The development of the amplicon vectors decsribed in this work provides another opportunity 
to design recombinant FMDV vaccines that have the advantages of safety, authentic 
antigenicity and most important, differentiation of infected from vaccinated animals by the 
lack of non-structural proteins like the 3D polymerase compared to infected animals. By 
using VLPs, there is no antibody response to internal or non-structural viral proteins induced, 
which allows the serological distinction between vaccinated and infected animals using 
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suitable diagnostic tests. The results obtained in mice in the present work are very promising 
as upon challenge with a high dose of virus, mice vaccinated with the amplicon vectors 
showed a reduction of viremia close to the animals vaccinated with the conventional vaccine. 
Also, the protection was better when using the amplicon vectors than adenovirus vectors. 
To summarize the presented work, the obtained results provide good evidence for the 
potential of HSV-1 amplicon vectors to be used for the development of a new vaccine 
strategy against FMDV and Rotavirus infections. 
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